[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23534
1. Malle D, Valeri RM, Photiou C, Kaplanis K, Andreadis C, Tsavdaridis D, Destouni C: Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology. Acta Cytol; 2005 Jan-Feb;49(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the diagnostic utility of E-cadherin (E-cad), N-cadherin (N-cad) and CD44 to discriminate adenocarcinoma cells from benign and malignant mesothelial cells in body cavity fluids and to clarify the origin of cancer cells.
  • STUDY DESIGN: A total of 120 ThinPrep (Cytyc Corp., Boxborough, Massachusetts, U.S.A.) cytologic specimens of serous effusions, which included 22 cases of reactive mesothelium, 6 cases of malignant mesothelioma and 92 cases of metastatic adenocarcinoma from various sites, were immunostained for E-cad, N-cad and CD44.
  • RESULTS: Eighty-three of 92 metastatic adenocarcinomas (90.21%) expressed E-cad, while 1 of 6 malignant mesotheliomas and 1 of 22 cases of reactive mesothelium were positive for E-cad.
  • All 6 cases of mesothelioma expressed N-cad, whereas most cases of metastatic adenocarcinomas were negative.
  • CD44 immunoreactivity was seen in 18 of 22 (81.81%) benign effusions and in 21 of 92 (22.82%) metastatic adenocarcinomas.
  • CONCLUSION: The combination of E-cad, N-cad and CD44 appears to be a useful panel for distinguishing metastatic adenocarcinoma, mesothelioma and reactive mesothelium and also for clarifying the exact histogenetic origin of cancer cells.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mesothelioma / pathology. Retrospective Studies


2. Lequin D, Fizazi K, Toujani S, Souquère S, Mathieu MC, Hainaut P, Bernheim A, Praz F, Busson P: Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary). BMC Cancer; 2007;7:225
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro culture of transplanted malignant cells.
  • Whenever possible, malignant xenografted or cultured cells were characterized by microsatellite genotyping, immunohistology, electron microscopy, multifish chromosome analysis and search of TP 53 gene mutations.
  • Both Capi1 and Capi3 have histological characteristics of adenocarcinomas and display intense expression of EMA, CEA and cytokeratin 7.
  • Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Neoplasm Transplantation / pathology. Neoplasms, Unknown Primary / genetics. Neoplasms, Unknown Primary / pathology. Transplantation, Heterologous / pathology
  • [MeSH-minor] Animals. Bone Neoplasms / secondary. Cell Line, Tumor. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 4 / genetics. Female. Genes, Neoplasm / genetics. Genes, p53 / genetics. Humans. Immunohistochemistry. Male. Mammary Neoplasms, Animal / secondary. Mice. Mice, Nude. Mice, SCID. Microsatellite Repeats / genetics. Microscopy, Electron. Mutation, Missense / genetics. Pleural Neoplasms / secondary. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Skin Neoplasms / secondary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):857-61 [17876336.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2026-36 [17698346.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):23-31 [12659667.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3479-82 [12972523.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):297-301 [15015611.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4952-60 [8756654.001]
  • [Cites] Diagn Mol Pathol. 1998 Oct;7(5):260-6 [9990484.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4765-9 [10519380.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):119-29 [15798092.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1284-7 [15976115.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):139-48 [17210693.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):391-406 [17368733.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • (PMID = 18088404.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2241840
  •  go-up   go-down


3. Moldvay J, Jäckel M, Páska C, Soltész I, Schaff Z, Kiss A: Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer; 2007 Aug;57(2):159-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: One hundred four lung cancer tissue blocks were studied including 46 adenocarcinomas (ADC), 30 squamous cell carcinomas (SCC), 15 small cell lung cancers (SCLC), 8 typical and 5 atypical carcinoids.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Bronchi / metabolism. Carcinoid Tumor / genetics. Carcinoid Tumor / metabolism. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Claudin-1. Claudin-3. Claudin-4. Claudins. Humans. Immunohistochemistry. RNA, Messenger / analysis. RNA, Messenger / metabolism. Respiratory Mucosa / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418912.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


Advertisement
4. Grotenhuis BA, van Heijl M, Wijnhoven BP, van Berge Henegouwen MI, Biermann K, ten Kate FJ, Busch OR, Dinjens WN, Tilanus HW, van Lanschot JJ: Lymphatic micrometastases in patients with early esophageal adenocarcinoma. J Surg Oncol; 2010 Dec 1;102(7):863-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic micrometastases in patients with early esophageal adenocarcinoma.
  • BACKGROUND: Both endoscopic and surgical treatments are recommended for m3- or sm1-adenocarcinomas of the esophagus, depending on patients' lymph nodal status.
  • Lymphatic dissemination is related to tumor infiltration depth, but varying incidences have been reported in m3- and sm1-adenocarcinomas.
  • METHODS: Sixty-three node-negative (N0) patients with early esophageal adenocarcinoma (m2/m3/sm1-tumors) were included.
  • Two m3-patients (3.2%) died due to disease recurrence, including one patient in whom an ITC was detected.
  • CONCLUSIONS: Lymphatic migration of tumor cells was found in node-negative m3- and sm1-adenocarcinomas of the esophagus (8.0% and 20.0%, respectively).
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratins / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20872812.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 68238-35-7 / Keratins
  •  go-up   go-down


5. Duan L, Wu AH, Sullivan-Halley J, Bernstein L: Passive smoking and risk of oesophageal and gastric adenocarcinomas. Br J Cancer; 2009 May 5;100(9):1483-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Passive smoking and risk of oesophageal and gastric adenocarcinomas.
  • Few studies have examined the association between passive smoking and the risk of oesophageal and gastric adenocarcinomas.
  • In a population-based case-control study with 2474 participants in Los Angeles County, there was no evidence that passive smoking had any appreciable effect on oesophageal or gastric adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1999 Oct;28(5):824-8 [10597977.001]
  • [Cites] Prev Med. 1984 Nov;13(6):680-90 [6536942.001]
  • [Cites] Am J Public Health. 1989 Feb;79(2):163-7 [2913834.001]
  • [Cites] Gut. 1998 Oct;43(4):537-41 [9824582.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):871-6 [10362132.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):461-8 [10473971.001]
  • [Cites] Alcohol. 2005 Apr;35(3):259-64 [16054988.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):689-701 [18293090.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Aug;12(8):837-42 [10958210.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):797-802 [11714107.001]
  • [Cites] Eur J Cancer Prev. 2002 Feb;11(1):27-38 [11917206.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438 [15285078.001]
  • [Cites] Free Radic Biol Med. 2000 Apr 1;28(7):1125-31 [10832074.001]
  • (PMID = 19352383.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES007048; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CN / N01CN25403; United States / NCI NIH HHS / CA / N01 CN025403; United States / NIEHS NIH HHS / ES / 5P30 ES07048
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Other-IDs] NLM/ PMC2694436
  •  go-up   go-down


6. Kim JH, Park SH, Yu ES, Kim MH, Kim J, Byun JH, Lee SS, Hwang HJ, Hwang JY, Lee SS, Lee MG: Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology; 2010 Oct;257(1):87-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations.
  • PURPOSE: To retrospectively determine the frequency, clinical and pathologic characteristics, and computed tomographic (CT) findings of visually isoattenuating pancreatic adenocarcinomas and to investigate the utility of magnetic resonance (MR) imaging and positron emission tomography (PET)/CT for detecting them.
  • Visually isoattenuating pancreatic adenocarcinoma was defined as lesion isoattenuation in both scan phases.
  • Serum levels of carbohydrate antigen 19-9, immunoglobulin G (IgG), and IgG fraction 4 (IgG4), survival after curative-intent surgery; and pathologic findings of visually isoattenuating pancreatic adenocarcinomas were analyzed.
  • CT findings of visually isoattenuating pancreatic adenocarcinomas and the sensitivity of MR imaging and PET/CT for detecting them were determined.
  • RESULTS: The frequency of visually isoattenuating pancreatic adenocarcinomas among pancreatic cancers was 5.4% (35 of 644).
  • Visually isoattenuating pancreatic adenocarcinoma, compared with usual pancreatic adenocarcinoma, was independently associated with a better survival after curative-intent surgery: Adjusted hazard ratio was 0.430 (P = .006).
  • Thirty surgically resected visually isoattenuating pancreatic adenocarcinomas were 1.5-4 cm (median, 3 cm).
  • Their pathologic findings differed from those of usual pancreatic adenocarcinomas: lower tumor cellularity, more frequent intratumoral acinar tissue and islet cells, and less prominent tumor necrosis.
  • Visually isoattenuating pancreatic adenocarcinomas showed various abnormalities at CT, which may suggest an isoattenuating mass or nodule.
  • CONCLUSION: Visually isoattenuating pancreatic adenocarcinoma represents a small but meaningful subset of pancreatic cancer and has characteristic clinical and pathologic features.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697118.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


7. Herawi M, Epstein JI: Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol; 2007 Jun;31(6):889-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
  • Overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in combination with absence of basal cell markers [ie, p63 and high molecular weight cytokeratin (HMWCK)] is typical of classic acinar prostatic adenocarcinoma.
  • We studied the expression and diagnostic utility of p63/HMWCK/AMACR immunohistochemical cocktail staining in ductal adenocarcinoma and cribriform Gleason pattern 4 acinar prostate cancer and compared it to noncribriform Gleason pattern 4 acinar prostate cancer.
  • One to 4 representative formalin-fixed paraffin-embedded archival tissue blocks from 62 radical prostatectomy specimens harboring prostate cancer of ductal (n=51), cribriform Gleason pattern 4 acinar (n=27), and noncribriform Gleason pattern 4 acinar adenocarcinoma (n=48) were included in this study.
  • The percentage of staining intensity and the presence of occasional basal cells positive with p63/HMWCK were recorded in each histologic type of prostatic adenocarcinoma.
  • Seventy-seven percent of ductal prostatic adenocarcinoma, 67% of cribriform acinar prostatic carcinoma, and 81% of noncribriform acinar prostatic carcinoma showed positive staining for AMACR.
  • In contrast, remnants of basal cells identified by p63/HMWCK were seen in a patchy fashion in a significant minority of both ductal and cribriform acinar prostatic adenocarcinoma, which most likely represents intraductal spread of tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Keratins / metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527076.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


8. Hammoud ZT, Badve S, Zhao Q, Li L, Saxena R, Thorat MA, Morimiya A, Rieger KM, Kesler KA: Differential gene expression profiling of esophageal adenocarcinoma. J Thorac Cardiovasc Surg; 2009 Apr;137(4):829-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression profiling of esophageal adenocarcinoma.
  • BACKGROUND: Differential gene expression offers an attractive means by which to study genes that may be involved in disease development and/or progression.
  • We performed quantitative gene expression in various stages of esophageal adenocarcinoma, treated exclusively by surgery with complete 2-field lymphadenectomy, in an attempt to discern genes involved in disease progression as well as genes that may predict survival.
  • RNA was extracted from 89 archived formalin-fixed, paraffin-embedded esophageal adenocarcinoma tissues.
  • CONCLUSIONS: Using differential gene expression of 502 known cancer genes, we identified genes that may be involved at various stages in the progression of esophageal adenocarcinoma.
  • These findings may provide further insight into the mechanisms of development and/or progression of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling
  • [MeSH-minor] Disease Progression. Humans. Neoplasm Staging. Predictive Value of Tests. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327504.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Bolton WD, Hofstetter WL, Francis AM, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG: Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg; 2009 Oct;138(4):831-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma.
  • INTRODUCTION: The impact of esophageal tumor length on pT1 esophageal adenocarcinoma has not been well evaluated.
  • METHODS: Case histories of all patients (n = 133) undergoing esophageal resection from 1979 to 2007 with pT1 adenocarcinoma of the esophagus were reviewed.
  • RESULTS: Patients with early-stage pT1 esophageal adenocarcinoma with tumors less than 3 cm demonstrate decreased long-term survival (3 years: >3 cm = 46% vs 93%; P < .001) and higher risk of lymph node involvement (lymph node positive: >3 cm = 47% vs 10%; P < .001).
  • In combination with submucosal involvement, esophageal tumor length (>3 cm) identifies a high-risk population of pT1 esophageal adenocarcinoma (3 years: group 1 [0 risk factors] = 100%, group 2 [1 risk factor] = 87%, and group 3 [2 risk factors] = 33%; P < .001).
  • CONCLUSIONS: This study demonstrates that esophageal tumor length (>3 cm) is a risk factor for long-term survival and lymph node involvement in early-stage pT1 esophageal adenocarcinoma.
  • Esophageal tumor length (>3 cm) in combination with submucosal involvement may help to identify a high-risk group of patients with pT1 esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Esophageal Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660349.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Piazuelo MB, Epplein M, Correa P: Gastric cancer: an infectious disease. Infect Dis Clin North Am; 2010 Dec;24(4):853-69, vii
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer: an infectious disease.
  • It has been estimated that about 18% of cancers are directly linked to infections, particularly gastric adenocarcinoma (Helicobacter pylori), cervical carcinoma (human papilloma viruses), and hepatocarcinoma (hepatitis B and C viruses).
  • Because gastric adenocarcinomas account for more than 90% of all gastric malignancies, this review focuses on adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Gastroenterology. 2009 Nov;137(5):1641-8.e1-2 [19664631.001]
  • [Cites] Lancet Oncol. 2009 Nov;10(11):1033-4 [19891056.001]
  • [Cites] Nat Rev Microbiol. 2009 Dec;7(12):887-94 [19898491.001]
  • [Cites] Carcinogenesis. 2010 Jan;31(1):100-10 [19934210.001]
  • [Cites] Am J Gastroenterol. 2010 Mar;105(3):493-8 [20203636.001]
  • [Cites] JAMA. 2010 May 5;303(17):1723-8 [20442388.001]
  • [Cites] Science. 2003 Mar 7;299(5612):1582-5 [12624269.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):569-73 [10749913.001]
  • [Cites] Nat Med. 2000 May;6(5):536-42 [10802709.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):264-73 [11274634.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1525-8 [11313896.001]
  • [Cites] Gut. 2001 Jun;48(6):743-7 [11358884.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] J Natl Cancer Inst. 1970 Feb;44(2):297-306 [11515071.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):683-92 [16388522.001]
  • [Cites] Microbes Infect. 2006 Jan;8(1):52-60 [16260169.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4766-72 [16899628.001]
  • [Cites] BMC Genomics. 2006;7:191 [16872520.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):632-7 [16932999.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):716-7 [16933014.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1674-87 [16985030.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1489-97 [16949645.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):915-8 [17287725.001]
  • [Cites] Arch Intern Med. 2007 Apr 23;167(8):821-7 [17452546.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):585-93 [17406989.001]
  • [Cites] J Natl Cancer Inst. 2007 Sep 5;99(17):1328-34 [17728213.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):813-29, vi [17996792.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):195-201 [18271915.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):279-87 [18308253.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):17-22 [11525302.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1348-53 [11729114.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):99 [11808612.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):252-66 [11854387.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] Lancet Oncol. 2001 Feb;2(2):88-94 [11905800.001]
  • [Cites] Eur J Cancer Prev. 2001 Dec;10(6):479-82 [11916345.001]
  • [Cites] Scand J Gastroenterol. 2002 May;37(5):517-22 [12059051.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2839-42 [12425557.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] Helicobacter. 2004 Jun;9(3):262-70 [15165263.001]
  • [Cites] J Natl Cancer Inst. 1968 Jan;40(1):43-68 [5635018.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1027-35 [1003539.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Gut. 1992 Apr;33(4):429-31 [1582581.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791-5 [8516329.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):324-9 [8168991.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):242-9 [8657240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14648-53 [8962108.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4255-9 [9766647.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Mol Microbiol. 1999 May;32(3):459-70 [10320570.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):747-9 [10328099.001]
  • [Cites] Hum Mutat. 1999;14(3):249-55 [10477433.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4823-8 [10519391.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):320-32 [15759043.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1464-9 [15941957.001]
  • [Cites] Gut. 2005 Nov;54(11):1536-40 [15985559.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):649-57 [16114018.001]
  • [Cites] J Pathol. 2006 Jan;208(2):233-48 [16362989.001]
  • [Cites] Helicobacter. 2008 Apr;13(2):135-45 [18321303.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1443-51 [18319718.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2655-63 [18442100.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):689-701 [18293090.001]
  • [Cites] Hum Pathol. 2008 Sep;39(9):1360-9 [18614201.001]
  • [Cites] Cancer Causes Control. 2008 Oct;19(8):869-77 [18369531.001]
  • [Cites] PLoS One. 2008;3(10):e3307 [18830403.001]
  • [Cites] J Med Microbiol. 2008 Dec;57(Pt 12):1445-53 [19018013.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Recent Results Cancer Res. 2009;181:223-9 [19213572.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] J Gastroenterol. 2009;44(4):239-48 [19271114.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):501-7 [19410194.001]
  • [Cites] Gastroenterology. 2009 May;136(6):1863-73 [19457415.001]
  • [Cites] Gastrointest Endosc. 2009 Jul;70(1):18-25 [19249770.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Intern Med. 2009 Jul 21;151(2):121-8 [19620164.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):824-33 [19445939.001]
  • (PMID = 20937454.001).
  • [ISSN] 1557-9824
  • [Journal-full-title] Infectious disease clinics of North America
  • [ISO-abbreviation] Infect. Dis. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA028842; United States / NCI NIH HHS / CA / P01 CA028842-25; United States / NCI NIH HHS / CA / P01-CA28842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS225304; NLM/ PMC2954127
  •  go-up   go-down


11. Billingham K, Radojkovic M: Osseous metaplasia of the colon in a diversion proctocolitis. Int J Surg Pathol; 2009 Feb;17(1):81-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osseous metaplasia within the gastrointestinal tract is a rare phenomenon, seen most frequently in mucinproducing left-sided colonic adenocarcinomas.
  • The diversion was performed following stricture formation, secondary to complicated diverticular disease with diverticular phlegmon formation.
  • [MeSH-minor] Aged. Humans. Ileostomy / adverse effects. Male. Metaplasia / diagnosis. Metaplasia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480393.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kono Y, Endo S, Otani S, Saito N, Hasegawa T, Sato Y, Sohara Y: [Non-tuberculous mycobacterial infection along the staple-suture line after segmentectomy for small peripheral lung cancer; report of a case]. Kyobu Geka; 2005 Feb;58(2):165-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60-year-old non-immunocompromised man who had undergone right upper lobectomy and subsequent left superior segmentectomy for small peripheral lung cancers (stage I well-differentiated adenocarcinomas) 2 years earlier, was referred to us for further investigation of an asymptomatic abnormal shadow observed on a chest radiograph.
  • Chest computed radiography showed air-space consolidation along the staple-suture line associated with the left superior segmentectomy, the abnormality was 4 x 5 x 5 cm.
  • Completion lower lobectomy was performed because transbronchial biopsy did not provide for a definite diagnosis.
  • [MeSH-minor] Adenocarcinoma / surgery. Humans. Lung Neoplasms / surgery. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724484.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 6
  •  go-up   go-down


13. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA: Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol; 2009 Jun 1;27(16):2598-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
  • PURPOSE: Adenocarcinomas of the small bowel and ampulla of Vater represent rare cancers that have limited data regarding first-line therapy.
  • We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin.
  • PATIENTS AND METHODS: Eligible patients with metastatic or unresectable tumors and no prior systemic chemotherapy for advanced disease participated in this phase II trial.
  • The confirmed overall response rate was 50%; three patients with metastatic disease achieved complete responses.
  • Subset analysis of patients with metastatic disease only (n = 25) revealed a median TTP of 9.4 months and median OS of 15.5 months.
  • CAPOX should be considered a new standard regimen for advanced small bowel and ampullary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ampulla of Vater / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Common Bile Duct Neoplasms / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA: Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol; 2005 Feb;36(2):170-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.
  • Guanylyl cyclase C (GC-C) is a receptor selectively expressed by intestinal epithelial cells whose persistent expression by colorectal carcinomas and ectopic expression by adenocarcinomas of the upper GI tract suggest its use as a marker for GI malignancies.
  • Expression was retained in tubular adenomas, inflammatory bowel disease, premalignant lesions, and in primary and metastatic adenocarcinomas from the colon, including metastases to lymph nodes and liver.
  • Moreover, GC-C was ectopically expressed in all cases of dysplasia and adenocarcinomas arising from intestinal metaplasia in esophagus and stomach.
  • Thus, GC-C appears to be an immunohistochemical marker for identifying adenocarcinomas of unknown origin, metastases in patients undergoing staging for GI adenocarcinomas, and intestinal metaplasia, dysplasia, and tumors arising therein in the upper GI tract.
  • [MeSH-major] Adenocarcinoma / enzymology. Gastrointestinal Neoplasms / enzymology. Gastrointestinal Tract / enzymology. Guanylate Cyclase / metabolism. Metaplasia / enzymology. Receptors, Peptide / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Intestinal Mucosa / enzymology. Intestinal Mucosa / pathology. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Receptors, Guanylate Cyclase-Coupled. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754294.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75123; United States / NCI NIH HHS / CA / CA79663; United States / NCI NIH HHS / CA / CA95026; United States / NCI NIH HHS / CA / R01 CA075123-06; United States / NIGMS NIH HHS / GM / R01 GM050290-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Peptide; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Guanylate Cyclase-Coupled; EC 4.6.1.2 / enterotoxin receptor
  •  go-up   go-down


15. Bitterlich N, Schneider J: Decision guarantee in tumour marker analysis: a cut-off independent assessment. Anticancer Res; 2007 Jul-Aug;27(4A):1933-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drawing from experiences with cut-off-oriented evaluation, the suggestion that diagnosis be made using a non-cut-off-based approach is discussed.
  • Histological classification of the tumour cases yielded 59 small cell carcinomas, 102 squamous cell carcinomas, 66 adenocarcinomas and 54 large cell carcinomas or mixed bronchial carcinomas without classification.
  • A determination of the sensitivity-adapted confidence in diagnosis should be made.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Models, Statistical
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. Female. Fuzzy Logic. Humans. Keratin-19. Keratins / blood. Male. Middle Aged. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649799.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


16. Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE: beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer; 2005 May;41(8):1127-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant association between beta-catenin expression (cytoplasmic and nuclear) and histological subtype and degree of differentiation was observed.
  • Mucinous carcinomas had the highest degree of cytoplasmic beta-catenin expression (92%), followed by endometroid (92%), mixed (90%), serous (82%), unclassified adenocarcinomas (81%), carcinomas clear cell and (70%), (P=0.01).
  • However, nuclear beta-catenin expression was strongly associated with endometroid histological subtype.
  • [MeSH-major] Cytoskeletal Proteins / metabolism. DNA, Neoplasm / genetics. Ovarian Neoplasms / genetics. Ploidies. Trans-Activators / metabolism
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Immunohistochemistry. Observer Variation. beta Catenin

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911235.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA, Neoplasm; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


17. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, Choti MA, Wolfgang CL: Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg; 2008 Jun;12(6):1061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Acinar cell carcinoma (ACC) is a rare, malignant neoplasm with a generally poor prognosis.
  • Median tumor size was 3.9 cm with 12 patients found to have stage IIB disease or worse.
  • Eight of the fourteen patients developed recurrent disease.
  • Overall median survival and disease-free survival were 33 and 25 months, respectively, as compared to a median survival of 18 months for pancreatic adenocarcinoma.
  • These lesions have a better prognosis than the more common pancreatic adenocarcinomas.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 1994 Jan;9(1):53-8 [8003821.001]
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Can Med Assoc J. 1962 Nov 3;87:970-3 [14011794.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Int Surg. 1984 Oct-Dec;69(4):361-4 [6084650.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1568-71 [15619219.001]
  • [Cites] Gut. 1990 Aug;31(8):953-5 [2387523.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):85-93 [3812876.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):772-7 [11072247.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):397-402 [4005804.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Gastroenterology. 1965 Nov;49(5):555-9 [5853162.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Am J Surg. 2006 Feb;191(2):191-7 [16442944.001]
  • (PMID = 17957440.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K: [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases]. Hinyokika Kiyo; 2007 Jul;53(7):489-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
  • We report two cases of combined small-cell carcinoma (SCC) and adenocarcinoma of prostate.
  • Needle biopsy of the prostate demonstrated both SCC and adenocarcinoma.
  • Only within the part of SCC, were neuroendocrine (NE) markers (chromogranin A [CgA], NCAM, and synaptophysin [SNP]) expressed.
  • The patient died three months after the diagnosis.
  • The symptom and elevated serum PSA (23.1 ng/ml) prompted prostatic needle biopsy, which demonstrated combined SCC/adenocarcinoma.
  • NE markers (CgA and SNP) were weakly expressed in the part of SCC.
  • Treatment of combined SCC and adenocarcinoma of prostate poses a dilemma.
  • In Case 1, MAB was effective for adenocarcinoma but not for SCC.
  • Much remains to be elucidated to better manage combined SCC/adenocarcinoma of prostate.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Small Cell. Neoplasms, Multiple Primary. Prostatic Neoplasms


19. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol; 2010;4(1):32-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of CD133 expression in stage I lung adenocarcinomas.
  • This study evaluated the potential prognostic value of CD133 expression in stage I lung adenocarcinomas (ADC).
  • Tumors from 177 patients were immunohistochemically examined for CD133 expression, and their associations with disease recurrence were analyzed.
  • CD133 high expressers showed a significantly higher risk of recurrence than CD133 low expressers: 5-year disease-free survival (DFS) rate 77.2% vs. 95.1% (p=0.004), adjusted Hazard ratio (HR) 4.37, 95% Confidence Interval (CI) 1.30-14.71 (p=0.017).
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / metabolism. Glycoproteins / metabolism. Lung Neoplasms / metabolism. Peptides / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Disease-Free Survival. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 2009 Nov 20;122(22):2763-9 [19951611.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):355-62 [19162366.001]
  • [Cites] Oncol Rep. 2009 Oct;22(4):709-17 [19724847.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6 [19805294.001]
  • [Cites] Lung Cancer. 2009 Dec;66(3):275-81 [19716622.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):950-8 [19676044.001]
  • [Cites] Cancer Res. 2010 Jan 15;70(2):719-29 [20068153.001]
  • [Cites] BMC Cancer. 2010;10:218 [20487522.001]
  • [Cites] Oncol Rep. 2010 Aug;24(2):537-46 [20596644.001]
  • [Cites] J Gastroenterol. 2010 Aug;45(8):896-902 [20379837.001]
  • [Cites] Oncol Rep. 2010 Nov;24(5):1201-12 [20878111.001]
  • [Cites] Prostate. 2011 Jan 1;71(1):18-25 [20583131.001]
  • [Cites] Med Oncol. 2011 Dec;28(4):1458-62 [20717756.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):45-51 [18196970.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] PLoS One. 2008;3(7):e2637 [18612434.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1285-9 [18781171.001]
  • [Cites] J Histochem Cytochem. 2008 Nov;56(11):977-93 [18645205.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8205-12 [19088037.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):71-8 [18790545.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2258-64 [19437567.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2018-25 [15545971.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 [17097610.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):341-8 [17350137.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 May;27(5):696-9 [17545092.001]
  • (PMID = 21228926.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  • [Other-IDs] NLM/ PMC3016102
  • [Keywords] NOTNLM ; CD133 / Lungadenocarcinoma / cancer stem cell / prognosis / stage I
  •  go-up   go-down


20. Lee CH, Bang SH, Lee SK, Song KY, Lee IC: Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. World J Gastroenterol; 2005 Apr 7;11(13):1937-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ.
  • METHODS: We analyzed the expression profiles of normal gastric pit, tubular adenoma and carcinoma in situ using microdissected cells from routine gastric biopsies.
  • RESULTS: In comparison with normal pit, adenoma/carcinoma showed 504 up-regulated and 29 down-regulated genes at the expected false significance rate 0.15%.
  • The differential expression between adenoma and carcinoma in situ was subtle: 50 and 22 genes were up-, and down-regulated in carcinomas at the expected false significance rate of 0.61%, respectively.
  • Differentially expressed genes were grouped according to patterns of the sequential changes for the 'tendency analysis' in the gastric mucosa-adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma in Situ / genetics. Gene Expression Profiling. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Animals. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800983.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305714
  •  go-up   go-down


21. Yang SH, Baek HA, Lee HJ, Park HS, Jang KY, Kang MJ, Lee DG, Lee YC, Moon WS, Chung MJ: Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep; 2010 Aug;24(2):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor tissues from 171 NSCLC, including 86 squamous cell carcinomas, 69 adenocarcinomas, and 16 pure bronchioloalveolar carcinomas (BAC), were analyzed for expression of DDR1 using immunohistochemical staining.
  • In addition, two lung adenocarcinoma cell lines (A549, H358) were transfected with two isoforms of DDR1, DDR1a and DDR1b, and then migration and invasion assays were carried out.
  • DDR1 up-regulation tend to be more frequently observed in invasive adenocarcinoma (64%) compared to DDR1 expression in BAC (38%) (p=0.056).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Receptor Protein-Tyrosine Kinases / physiology. Receptors, Mitogen / physiology
  • [MeSH-minor] Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Cell Adhesion / genetics. Cell Movement / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pleural Neoplasms / metabolism. Pleural Neoplasms / secondary. Prognosis. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596615.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Mitogen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor
  •  go-up   go-down


22. Krockenberger M, Honig A, Rieger L, Coy JF, Sutterlin M, Kapp M, Horn E, Dietl J, Kammerer U: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):101-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The energy resources of fully malignant transformed carcinomas are mainly supplied by aerobic glycolysis, for which several pathways are known.
  • In order to investigate the role of TKTL1 for the progression of ovarian carcinomas, we examined paraffin sections of normal ovarian tissues, ovarian borderline tumors, and mucinous or serous papillary ovarian adenocarcinomas with respect to their expression of TKTL1.
  • We identified a significantly elevated expression of TKTL1 in serous papillary ovarian adenocarcinomas, which correlates with poor prognostic parameters in the examined study group.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Paraffin Embedding

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291239.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.2.1.1 / TKTL1 protein, human; EC 2.2.1.1 / Transketolase
  •  go-up   go-down


23. Mahajan A, Ho H, Jain A, Rehan ME, Northup PG, Phillips MS, Ellen K, Shami VM, Kahaleh M: Mortality in patients undergoing covered self-expandable metal stent revisions in malignant biliary stricture: does pathology matter? Dig Liver Dis; 2010 Nov;42(11):803-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality in patients undergoing covered self-expandable metal stent revisions in malignant biliary stricture: does pathology matter?
  • BACKGROUND AND AIMS: Partially covered metal stents have been extensively used for palliation of obstructive jaundice in malignant distal biliary strictures and can be removed in cases of malfunction or need for tissue diagnosis.
  • METHODS: Patients with a distal malignant biliary obstruction palliated with a partially covered metal stent were followed-up prospectively over 5 years until malfunction or death.
  • Multivariate analysis was performed on non-surgical patients to assess for independent predictors of death using known risk factors including type of malignancy (adenocarcinoma versus all others), age greater than 55, gender, and exposure to adjuvant chemotherapy and/or radiotherapy.
  • Logistic regression analysis in the 31 patients with unresectable disease showed that a histologic diagnosis of adenocarcinoma was associated with increased mortality post partially covered metal stents revision.
  • CONCLUSIONS: Partially covered metal stents revision should be undertaken especially when dealing with a non-adenocarcinoma type cancer.
  • [MeSH-major] Adenocarcinoma. Cholestasis / therapy. Device Removal. Pancreatic Neoplasms. Stents / adverse effects

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • [CommentIn] Dig Liver Dis. 2010 Nov;42(11):765-6 [20869924.001]
  • (PMID = 20347619.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK067629
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Jain D, Joshi K, Jindal SK: Precursor lesions of adenocarcinoma lung--two case reports. Indian J Pathol Microbiol; 2005 Jul;48(3):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions of adenocarcinoma lung--two case reports.
  • Although precursor lesions of bronchogenic squamous cell carcinoma are well documented, the preinvasive lesions of pulmonary adenocarcinoma are seen very rarely.
  • It has been hypothesized that there is a stepwise progression of alveolar epithelial hyperplasia to atypical alveolar hyperplasia and subsequently to malignancy in the pathogenesis of peripheral adenocarcinoma of the lung.
  • In the present paper we would like to share our experience of two cases of pulmonary adenocarcinoma with their precursor lesions in the form of atypical alveolar hyperplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Diseases, Interstitial / pathology. Lung Neoplasms / pathology. Precancerous Conditions / pathology. Pulmonary Alveoli / pathology

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761769.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


25. Furukawa T: Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg; 2007;14(3):233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary-mucinous neoplasms of the pancreas show characteristic clinicopathological and molecular pathobiological features which are distinct from those of conventional ductal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Papillary / genetics. Biomarkers, Tumor / genetics. Carcinoma, Pancreatic Ductal / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Disease Progression. Dual Specificity Phosphatase 6 / genetics. Dual Specificity Phosphatase 6 / metabolism. Humans. Prognosis. Smad4 Protein / genetics. Smad4 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520197.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; EC 3.1.3.48 / DUSP6 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 6
  • [Number-of-references] 47
  •  go-up   go-down


26. Bosserhoff AK, Grussendorf-Conen EI, Rübben A, Rudnik-Schöneborn S, Zerres K, Buettner R, Merkelbach-Bruse S: Multiple colon carcinomas in a patient with Cowden syndrome. Int J Mol Med; 2006 Oct;18(4):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cowden syndrome is a non-adenomatous gastrointestinal polyposis syndrome with inactivation of PTEN, a dual-phosphatase tumor suppressor gene.
  • Patients with loss of wildtype PTEN expression from one allele carry an increased risk of malignant breast, thyroid and brain tumors.
  • However, the risk of malignant transformation in gastrointestinal polyps is still unclear.
  • Progression to invasive adenocarcinoma occured in two pre-existing hamartomatous polyps.
  • This case demonstrates that gastrointestinal hamartomas in Cowden syndrome patients can progress to invasive adenocarcinomas and should therefore be carefully monitored.

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964417.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / RNA, Messenger; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


27. Gurevich LE, Kazantseva IA, Korsakova NA, Tsar'kov PV, Polishchuk LO: [Expression of type 1 and type 2 mucins in colonic epithelial tumors]. Arkh Patol; 2007 Mar-Apr;69(2):12-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of MUC-1 and MUC-2 was investigated with immunohistochemical staining (PAP-method) in 5 cases of adenomas and in 60 cases of colorectal adenocarcinomas.
  • The expression of MUC-1 and MUC-2 can be useful for diagnosis and prognosis in patients with colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma. Antigens, Neoplasm / biosynthesis. Colonic Neoplasms. Intestinal Mucosa. Mucins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642184.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


28. Iizasa T, Baba M, Saitoh Y, Suzuki M, Haga Y, Iyoda A, Chang H, Hiroshima K, Itoga S, Tomonaga T, Nomura F, Fujisawa T: A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population. Oncol Rep; 2005 Oct;14(4):919-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population.
  • There was a statistically significant difference in genotype distribution between the lung adenocarcinoma and control group (P=0.0088, A4/A4 vs. non-A4/A4).
  • In the lung adenocarcinoma group, the univariate risk estimates for the A4/A4 subgroup compared to the most common subgroup (A2/A2) was 4.300 (95% confidence interval = 1.358-13.618, P=0.0131).
  • We conclude that the A4/A4 genotype of the 5'-flanking region of CYP2E1 was significantly more frequent in lung adenocarcinoma cases than in healthy controls and, therefore, may be involved in the development of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Cytochrome P-450 CYP2E1 / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Base Sequence. Carcinogens. Case-Control Studies. DNA / chemistry. DNA / metabolism. Dimethylnitrosamine. Female. Genetic Predisposition to Disease. Genotype. Humans. Japan. Male. Models, Genetic. Molecular Sequence Data. Nitrosamines. Odds Ratio. Polymerase Chain Reaction. Regression Analysis. Repetitive Sequences, Nucleic Acid. Risk. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. N-NITROSODIMETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142352.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 9007-49-2 / DNA; EC 1.14.13.- / Cytochrome P-450 CYP2E1; M43H21IO8R / Dimethylnitrosamine
  •  go-up   go-down


29. Brüning A, Jückstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I: The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol; 2010 11;25(11):1447-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas.
  • Therefore, the aim of this study was to investigate the expression of this protein in endometrial adenocarcinomas and to analyse potential correlations between this nuclear transcription factor and estrogen receptors in endometrial adenocarcinomas.
  • Additionally, we evaluated whether MTA3 might be a prognostic parameter in endometrioid adenocarcinomas.
  • Endometrioid adenocarcinomas were obtained from 200 patients and immunohistochemically analysed for MTA3 and estrogen receptor alpha and beta (ER-alpha and ER-beta) expression.
  • Overall, endometrioid adeno-carcinomas of histological differentiation grade 3 demonstrated a significantly lower expression of MTA3 compared to carcinomas of histological grade 1 and 2 (p<0.05).
  • MTA3 expression is reduced in endometrioid adenocarcinomas of poor differentiation, though without any correlation to ER-alpha and ER-beta expression.
  • Overall, MTA3 did not constitute an independent prognostic factor in this study, suggesting that MTA3 is not a useful marker to assess and identify high-risk patients with endometrial adenocarcinomas.
  • Still, the downregulation of MTA3 predispose this cell type to be of high metastatic potential after malignant transformation, playing an essential, but as yet unknown role in human endometrial carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Down-Regulation. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / biosynthesis. Receptors, Estrogen / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20865667.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MTA3 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  •  go-up   go-down


30. Hirano K, Miyahara S, Sugiyama S, Kajiwara H: [A case of metachronous double primary adenocarcinoma in both lungs]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1549-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metachronous double primary adenocarcinoma in both lungs].
  • A 78-year-old man underwent a right lower lobectomy for adenocarcinoma in January 2004.
  • We diagnosed adenocarcinoma from the specimen.
  • We experienced two adenocarcinomas as metachronous double primary lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716884.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Begum M, Tashiro H, Katabuchi H, Suzuki A, Kurman RJ, Okamura H: Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab Invest; 2006 Mar;86(3):286-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of CAH and adenocarcinomas of the endometrium was significantly decreased by the neonatal estrogenic treatments in the mPTEN+/- mice.
  • Coincidentally, all treatments significantly decreased the stromal cell density, and CAH and adenocarcinomas rarely developed in the epithelium adjacent to the affected endometrial stroma.
  • [MeSH-major] Adenocarcinoma / prevention & control. Endometrial Neoplasms / prevention & control. Gene Expression Regulation, Neoplastic / drug effects. PTEN Phosphohydrolase / genetics. Phytoestrogens / pharmacology
  • [MeSH-minor] Animals. Animals, Newborn. Disease Models, Animal. Female. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Mice. Mice, Inbred C57BL. Organ Size / drug effects. RNA, Messenger / metabolism. Recombination, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Uterus / metabolism. Uterus / pathology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402032.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Hoxa11 protein, mouse; 0 / Phytoestrogens; 0 / RNA, Messenger; 164384-16-1 / Hoxa10 protein, mouse; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


32. Koyama H, Ohno Y, Aoyama N, Onishi Y, Matsumoto K, Nogami M, Takenaka D, Nishio W, Ohbayashi C, Sugimura K: Comparison of STIR turbo SE imaging and diffusion-weighted imaging of the lung: capability for detection and subtype classification of pulmonary adenocarcinomas. Eur Radiol; 2010 Apr;20(4):790-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of STIR turbo SE imaging and diffusion-weighted imaging of the lung: capability for detection and subtype classification of pulmonary adenocarcinomas.
  • OBJECTIVE: The aim of the study was to evaluate the diagnostic performance of diffusion-weighted imaging (DWI) for detection and subtype classification in pulmonary adenocarcinomas through comparison with short TI inversion recovery turbo spin-echo imaging sequence (STIR).
  • METHODS: Thirty-two patients (mean age, 65.2 years) with 33 adenocarcinomas (mean diameter, 27.6 mm) were enrolled in this study.
  • The ADC values on DWI and the contrast ratio (CR) between cancer and muscle on STIR were measured and those were compared across subtype classifications.
  • Finally, ROC-based positive tests were performed to differentiate subtype classifications, and differentiation capabilities were compared.
  • The ADC values showed no significant difference regarding subtype classification; however, the CRs of bronchio-alveolar carcinomas (BACs) were significantly lower than those of other types (P < 0.05).
  • For differentiating adenocarcinomas with mixed subtypes from those with no BA component, there were no significant differences between the two sequences.
  • CONCLUSION: STIR is more sensitive for detection and subtype classification than DWI.
  • [MeSH-major] Adenocarcinoma / diagnosis. Algorithms. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Lung / pathology. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Imaging. 2006 Sep 13;6:135-43 [17015238.001]
  • [Cites] Med Phys. 1987 Jan-Feb;14(1):1-37 [3031439.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):541-5 [6625722.001]
  • [Cites] Eur Radiol. 2008 Oct;18(10):2120-31 [18458913.001]
  • [Cites] Radiology. 2004 Jun;231(3):872-9 [15163823.001]
  • [Cites] Radiology. 2001 Sep;220(3):621-30 [11526259.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] Radiology. 1988 Aug;168(2):497-505 [3393671.001]
  • [Cites] J Magn Reson Imaging. 2000 Apr;11(4):343-50 [10767062.001]
  • [Cites] AJR Am J Roentgenol. 2008 Aug;191(2):464-70 [18647918.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):208-13 [12595105.001]
  • [Cites] Radiology. 2002 Aug;224(2):503-11 [12147849.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1622-35 [17515386.001]
  • [Cites] APMIS. 1989 Aug;97(8):689-98 [2669853.001]
  • [Cites] Eur Radiol. 1997;7(8):1190-4 [9377498.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):71-8 [15208113.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):73-81 [17154370.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):358-64 [18379353.001]
  • [Cites] AJR Am J Roentgenol. 2005 Oct;185(4):979-84 [16177419.001]
  • [Cites] Magn Reson Med. 1995 May;33(5):697-712 [7596275.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] Eur Radiol. 1999;9(9):1755-64 [10602947.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):763-8 [10701622.001]
  • [Cites] Stroke. 1992 May;23(5):746-54 [1374575.001]
  • [Cites] Eur Radiol. 2006 Jul;16(7):1468-77 [16557366.001]
  • [Cites] Radiology. 1986 Aug;160(2):299-305 [3726104.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):465-9 [10430155.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Radiology. 2007 May;243(2):570-7 [17400757.001]
  • (PMID = 19763578.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


33. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr, Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest; 2005 Jan;35(1):60-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four peptide hormones decrease the number of human breast adenocarcinoma cells.
  • METHODS AND MATERIALS: These six hormones, each at their 1-microm concentrations, were evaluated for their ability to decrease the number and/or proliferation of breast adenocarcinoma cells in culture for 24, 48, 72, and 96 h.
  • RESULTS: Within 24 h, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, atrial natriuretic peptide and 8-bromo-cyclic GMP, a cell-permeable analogue of their intracellular mediator cyclic GMP (each at 1 microm), decreased the number of breast adenocarcinoma cells 60%, 31%, 27%, 40%, and 31%, respectively.
  • There was no proliferation in the 3 days following this decrease in breast adenocarcinoma cell number.
  • Brain natriuretic peptide and CNP did not decrease the number of breast adenocarcinoma cells or inhibit their DNA synthesis.
  • Natriuretic peptide receptors-A and -C were present in the breast adenocarcinoma cells.
  • CONCLUSIONS: Four peptide hormones significantly decrease the number of human breast adenocarcinoma cells within 24 h and inhibit the proliferation of these cells for at least 96 h.
  • [MeSH-major] Adenocarcinoma / drug therapy. Breast Neoplasms / drug therapy. Hormones / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638821.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / atrial natriuretic factor precursor (79-98); 0 / atrial natriuretic factor prohormone (1-30), human; 0 / atrial natriuretic factor prohormone (31-67); 114471-18-0 / Natriuretic Peptide, Brain; 127869-51-6 / Natriuretic Peptide, C-Type; 85637-73-6 / Atrial Natriuretic Factor; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Atrial Natriuretic Factor; EC 4.6.1.2 / atrial natriuretic factor receptor A; EC 4.6.1.2 / atrial natriuretic factor receptor C
  •  go-up   go-down


34. Nashimoto A, Yabusaki H, Nakagawa S: [Proper follow-up schedule after curative gastric surgery]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1402-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were many peritoneal and remote lymph nodal recurrences in undifferentiated adenocarcinomas, and hematological recurrences in differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Critical Pathways. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755807.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Ramani VC, Hennings L, Haun RS: Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer; 2008;8:373
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The levels of immunoreactive Dsg1 and Dsg2 were reduced in pancreatic adenocarcinomas compared with both normal pancreatic and chronic pancreatitis tissues.
  • Using in vitro degradation assays, both Dsg1 and Dsg2 could be readily proteolyzed by hK7, which is overexpressed in pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Desmoglein 2 / metabolism. Kallikreins / metabolism. Pancreatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 15;86(10):2074-82 [10570434.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1235-44 [15140227.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):208-16 [11252896.001]
  • [Cites] Pathol Res Pract. 2001;197(2):85-91 [11261822.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]
  • [Cites] Biochim Biophys Acta. 2001 Nov 30;1552(1):39-45 [11781114.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61 [11906548.001]
  • [Cites] Exp Dermatol. 2002 Apr;11(2):115-25 [11994138.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):255-68 [12007186.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58 [12784999.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):283-8 [15297163.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1001-6 [15492784.001]
  • [Cites] Br J Urol. 1990 Feb;65(2):176-80 [2317652.001]
  • [Cites] Annu Rev Cell Biol. 1990;6:461-91 [2275820.001]
  • [Cites] Arch Dermatol Res. 1991;283(2):108-12 [1712574.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):353-7 [1729705.001]
  • [Cites] Breast Cancer Res Treat. 1993;24(3):175-84 [8435473.001]
  • [Cites] Semin Cancer Biol. 1993 Aug;4(4):219-29 [8400144.001]
  • [Cites] Semin Cancer Biol. 1993 Aug;4(4):251-8 [8400147.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):204-12 [7540167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Differentiation. 1996 May;60(2):99-108 [8641550.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1491-7 [8664118.001]
  • [Cites] Br J Dermatol. 1996 Mar;134(3):460-4 [8731669.001]
  • [Cites] World J Urol. 1996;14(3):151-6 [8806193.001]
  • [Cites] J Cell Biol. 1997 Jul 14;138(1):193-201 [9214392.001]
  • [Cites] J Cell Sci. 1998 Feb;111 ( Pt 4):495-509 [9443898.001]
  • [Cites] Int Rev Cytol. 1999;185:237-302 [9750269.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1260-6 [15766562.001]
  • [Cites] J Pathol. 2005 Oct;207(2):199-206 [16025435.001]
  • [Cites] J Invest Dermatol. 2006 Jul;126(7):1622-32 [16628198.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2397-403 [16890424.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):3640-52 [17158887.001]
  • [Cites] Cancer. 2007 May 1;109(9):1811-20 [17354228.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1783-7 [17519903.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):906-16 [17640963.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1169-73 [18343220.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):51-6 [12759751.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 19091121.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DSG1 protein, human; 0 / DSG2 protein, human; 0 / DSG3 protein, human; 0 / Desmoglein 1; 0 / Desmoglein 2; 0 / Desmoglein 3; 0 / RNA, Messenger; 0 / Recombinant Proteins; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2628383
  •  go-up   go-down


36. Tsai WC, Sheu LF, Chao YC, Chen A, Chiang H, Jin JS: Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients. Chin J Physiol; 2007 Oct 31;50(5):225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.
  • We tested the expressions of matriptase and hepatocyte growth factor activator inhibitor-1 (HAI-1) maybe associated with the progression of colorectal adenocarcinoma.
  • Immunohistochemical analysis of matriptase and HAI-1 was performed in tissue microarray slides of 91 colorectal adenocarcinomas with various degrees.
  • The matriptase scores in moderately (346.7 +/- 10.6) and poorly differentiated (248.1 +/- 12.9) were significantly lower than those in well differentiated (368.4 +/- 9.6) colorectal adenocarcinomas.
  • The matriptase/HAI-1 ratios in poorly (1.8 +/- 0.4) and moderately differentiated (1.8 +/- 0.3) were significantly lower than in well differentiated (2.2 +/- 0.2) colorectal adenocarcinomas.
  • Otherwise, the matriptase scores and matriptase/HAI-1 ratio showed significant reverse correlation with more advanced TNM stages of colorectal adenocarcinomas in Chinese patients.
  • In conclusion, pharmacological inhibitors of matriptase may not be effective treatment for advanced colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Asian Continental Ancestry Group. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / pathology. Proteinase Inhibitory Proteins, Secretory / metabolism. Serine Endopeptidases / metabolism
  • [MeSH-minor] Aged. China. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274158.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINT1 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  •  go-up   go-down


37. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A: p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer; 2010 Jan-Mar;47(1):31-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Genetic Predisposition to Disease. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071787.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


38. Lagergren J, Jansson C: Sex hormones and oesophageal adenocarcinoma: influence of childbearing? Br J Cancer; 2005 Oct 17;93(8):859-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex hormones and oesophageal adenocarcinoma: influence of childbearing?
  • The male predominance of oesophageal adenocarcinoma might be explained by oestrogen protection in women.
  • The influence of childbearing on the risk of oesophageal adenocarcinoma was investigated in a Swedish population-based case (n=63) -control (n=141) study.
  • In conclusion, we found no inverse association between childbearing and oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / physiopathology. Esophageal Neoplasms / physiopathology. Estrogens / physiology. Infertility, Female / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • (PMID = 16189516.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  • [Other-IDs] NLM/ PMC2361653
  •  go-up   go-down


39. Belushkina NN: [Peculiarities of regulation of tumour cell apoptosis]. Vestn Ross Akad Med Nauk; 2008;(10):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 3.5-fold rise in BCL-2 expression was documented in a group of moderately differentiated adenocarcinomas and undifferentiated tumours.
  • The most striking (9-fold) difference between BCL expression in untransformed and atypical cells was recorded in moderately differentiated metastatic colonic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140394.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  • [Number-of-references] 32
  •  go-up   go-down


40. Ishii N, Setoyama T, Matsuda M, Suzuki S, Uemura M, Iizuka Y, Fukuda K, Suzuki K, Fujita Y: Superficial tumors involving terminal ileum treated by endoscopic submucosal dissection. Clin J Gastroenterol; 2010 Oct;3(5):226-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both resected specimens showed intramucosal adenocarcinomas with clear lateral and vertical margins.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 1980 Jan;25(1):33-41 [7353449.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):690-4 [12929067.001]
  • [Cites] Gastrointest Endosc. 2004 Mar;59(3):443-6 [14997153.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jun;5(6):678-83; quiz 645 [17466600.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):966-73 [17524403.001]
  • [Cites] Virchows Arch. 2003 Feb;442(2):99-106 [12596058.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] Digestion. 1978;18(5-6):329-36 [750260.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):303-9 [1607080.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):335-42 [19517169.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):125-8 [11756934.001]
  • [Cites] Surg Endosc. 2010 Aug;24(8):1941-7 [20112112.001]
  • (PMID = 26190325.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Colonic tumor / Endoscopic submucosal dissection / Terminal ileum
  •  go-up   go-down


41. Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C: A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer; 2006;6:278
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinomas of the lung, this latter as a positive control for mutation detection.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2001;197(2):95-100 [11261824.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6657-63 [16170173.001]
  • [Cites] Yi Chuan Xue Bao. 2001;28(9):793-800 [11582736.001]
  • [Cites] J Hepatol. 2002 Jun;36(6):780-5 [12044528.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):355-7 [12379854.001]
  • [Cites] Dig Liver Dis. 2003 May;35(5):332-8 [12846405.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8105-8 [16299242.001]
  • [Cites] Pharmacogenet Genomics. 2006 Jan;16(1):73-4 [16344724.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 1995 Apr;24(2):93-5 [7788735.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):1055-9 [7645925.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1377-83 [11355950.001]
  • (PMID = 17150109.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC1712353
  •  go-up   go-down


42. Gockel I, Lang H: [Squamous cell carcinoma of the oesophagus--impact of surgery within the therapeutic concept]. Z Gastroenterol; 2010 May;48(5):560-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinomas of the oesophagus are a completely different entity from adenocarcinomas in regard to their aetiopathology, tumour biology, co-morbidity, operative risk, and prognosis.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Disease-Free Survival. Esophagectomy. Esophagoscopy. Humans. Lymphatic Metastasis / pathology. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449788.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 55
  •  go-up   go-down


43. Horio Y, Osada H, Shimizu J, Ogawa S, Hida T, Sekido Y: Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines. Cancer Chemother Pharmacol; 2010 Jul;66(2):237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Engineered-mice with low amounts of RanBP2 have been reported to form lung adenocarcinomas.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19809814.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Coloring Agents; 0 / Isoenzymes; 0 / Molecular Chaperones; 0 / Nuclear Pore Complex Proteins; 0 / RNA, Messenger; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / ran-binding protein 2; 298-93-1 / thiazolyl blue; 93N13LB4Z2 / amrubicin; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


44. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, Volante M, Scagliotti GV, Papotti M: Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology; 2009 Jul;55(1):20-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases.
  • None of the pure bronchioloalveolar carcinomas proved to be positive, vs. 42.8% of the large cell carcinomas (neuroendocrine subtype excluded).
  • Adenocarcinomas (8.5%), large cell neuroendocrine carcinomas (20%) and squamous cell carcinomas (29.6%) displayed an intermediate percentage of positive cases, suggesting a gradient of Cav-1 expression according to tumour histotype-related aggressiveness.
  • In 34 tumours metastatic to the brain, primary and secondary lesions were compared and 53% of brain metastases were Cav-1+ vs. 20.6% of primaries, indicating a de novo acquisition of Cav-1 expression.
  • CONCLUSIONS: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Caveolin 1 / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / secondary. DNA, Neoplasm / genetics. Disease Progression. Gene Amplification / genetics. Gene Expression Regulation, Neoplastic. Humans. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614763.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


45. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA: Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia; 2007 Feb;9(2):128-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in vascular permeability and blood flow of syngeneic CT-26 murine colon adenocarcinomas were assessed at 4 and 24 hours after DMXAA treatment (30 mg/kg, i.p.) and correlated with induction of tumor necrosis factor-alpha (TNF-alpha), endothelial damage [CD31/terminal deoxynucleotidyl transferase (TdT)], and treatment outcome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Capillary Permeability / drug effects. Colonic Neoplasms / drug therapy. Endothelium, Vascular / drug effects. Magnetic Resonance Imaging / methods. Microscopy / methods. Xanthones / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Contrast Media. Drug Delivery Systems. Drug Screening Assays, Antitumor. Female. Hemorrhage / chemically induced. Mice. Mice, Inbred BALB C. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Transplantation / methods. Pentetic Acid / analogs & derivatives. Polylysine / analogs & derivatives. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Skin Window Technique. Transplantation, Heterotopic. Transplantation, Isogeneic. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):798-802 [10597197.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):534-42 [16867215.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):197-207 [10935474.001]
  • [Cites] NMR Biomed. 2002 Apr;15(2):99-105 [11870905.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1937-42 [12085190.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1334-9 [12149215.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3826-40 [12228202.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1503-11 [12459378.001]
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] Br J Radiol. 2003;76 Spec No 1:S60-80 [15456715.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2142-6 [6992981.001]
  • [Cites] Br J Cancer. 1982 Jan;45(1):136-9 [7059456.001]
  • [Cites] Cancer Res. 1988 Apr 15;48(8):2179-83 [3349488.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4478-84 [2369726.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):265-73 [1988088.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4265-8 [1638539.001]
  • [Cites] Radiology. 1993 Jun;187(3):701-6 [8497616.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(2):143-8 [7767951.001]
  • [Cites] Crit Care Med. 1996 Sep;24(9):1543-6 [8797629.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):633-8 [9973211.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1252-8 [10096556.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):322-6 [15800918.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):423-35 [15928673.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9253-60 [16230386.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):199-206 [16611413.001]
  • [Cites] Oncologist. 2006 Apr;11(4):397-408 [16614236.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • (PMID = 17356709.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00119275
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / P01 CA055791; United States / NCI NIH HHS / CA / R01CA89656; United States / NCI NIH HHS / CA / R01 CA089656; United States / NCI NIH HHS / CA / P01CA55791
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tumor Necrosis Factor-alpha; 0 / Xanthones; 0 / methoxy-polyethylene glycol-succinyl-polylysine-GdDTPA; 0829J8133H / vadimezan; 25104-18-1 / Polylysine; 7A314HQM0I / Pentetic Acid
  • [Other-IDs] NLM/ PMC1813934
  •  go-up   go-down


46. Wikman H, Ruosaari S, Nymark P, Sarhadi VK, Saharinen J, Vanhala E, Karjalainen A, Hollmén J, Knuutila S, Anttila S: Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene; 2007 Jul 12;26(32):4730-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In adenocarcinomas, AI in 19p appeared to occur independently of the asbestos exposure.
  • [MeSH-major] Adenocarcinoma / chemically induced. Allelic Imbalance. Asbestos / toxicity. Carcinogens / toxicity. Chromosomes, Human, Pair 19 / genetics. Lung Neoplasms / chemically induced. Occupational Exposure


47. Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, Murray GI: Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol; 2006 Nov;210(3):351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we used comparative proteomic analysis to show that t-complex protein subunits TCP1 beta and TCP1 epsilon are over-expressed in colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Chaperonins / genetics. Colorectal Neoplasms / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Neoplasm / immunology. Cell Nucleus / chemistry. Cell Nucleus / genetics. Chaperonin Containing TCP-1. Cytoplasm / chemistry. Cytoplasm / genetics. Female. Gene Expression / genetics. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Proteomics. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16981251.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Neoplasm Proteins; 0 / TCP1 protein, human; EC 3.6.1.- / Chaperonin Containing TCP-1; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


48. Koukourakis MI, Giatromanolaki A, Polychronidis A, Simopoulos C, Gatter KC, Harris AL, Sivridis E: Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci; 2006 Jul;97(7):582-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a series of 79 colorectal adenocarcinomas we investigated the role of anemia in activating molecular pathways regulated by hypoxia.
  • [MeSH-major] Adenocarcinoma / pathology. Anemia / diagnosis. Anoxia / diagnosis. Basic Helix-Loop-Helix Transcription Factors / analysis. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827797.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNIP3 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DEC1 protein, human; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Isoenzymes; 0 / MCTS1 protein, human; 0 / Membrane Proteins; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins; 0 / SLC2A1 protein, human; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / endothelial PAS domain-containing protein 1; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 5
  •  go-up   go-down


49. Avenhaus W, Kemper B, Knoche S, Domagk D, Poremba C, von Bally G, Domschke W: Dynamic holographic endoscopy--ex vivo investigations of malignant tumors in the human stomach. Lasers Med Sci; 2005;19(4):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic holographic endoscopy--ex vivo investigations of malignant tumors in the human stomach.
  • By connecting a mobile electronic speckle pattern interferometry (ESPI) camera system (light source: double frequency Nd:YAG laser, lambda = 532 nm) to different types of endoscopes, ex vivo experiments were performed on ten formalin fixed human stomachs, nine containing adenocarcinomas and one with a gastric lymphoma.
  • Our ex vivo investigations of malignant gastric tumors show that the application of dynamic holographic endoscopy makes it possible to distinguish areas of malignancy from surrounding healthy tissue based on the differences in tissue elasticity.
  • [MeSH-minor] Adenocarcinoma / pathology. Fiber Optic Technology. Humans. Image Processing, Computer-Assisted. Lasers. Lymphoma / pathology. Photography / instrumentation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Heart Valve Dis. 1993 May;2(3):343-7 [8269130.001]
  • [Cites] Appl Opt. 2000 Aug 1;39(22):3899-905 [18349967.001]
  • [Cites] J Heart Valve Dis. 1993 Jul;2(4):440-7 [8269147.001]
  • [Cites] Ann Thorac Surg. 1998 Dec;66(6 Suppl):S206-11 [9930449.001]
  • [Cites] Gastrointest Endosc. 2001 Oct;54(4):496-500 [11577317.001]
  • [Cites] J Heart Valve Dis. 1993 Jul;2(4):448-53 [8269148.001]
  • (PMID = 15726298.001).
  • [ISSN] 0268-8921
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Chantranuwat C, Sriuranpong V, Huapai N, Chalermchai T, Leungtaweeboon K, Voravud N, Mutirangura A: Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. J Med Assoc Thai; 2005 Sep;88 Suppl 4:S322-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
  • Almost the mutations were present in adenocarcinomas.
  • Few had studied on histopathologic correlation with EGFR mutation in pulmonary adenocarcinomas.
  • To obtain better view on pathobiology of pulmonary adenocarcinomas, we correlated exons 19 and 21 mutations with various histopathologic features by dissecting particular histological patterns from 60 surgically resected adenocarcinomas.
  • CONCLUSION: High frequency of the mutation does not present only in BAC pattern, but also in well-formed and poorly-formed acinar patterns, suggesting them as usual spectrum of EGFR mutated adenocarcinomas.
  • Other characteristics of EGFR-mutated adenocarcinomas include TRU-type histology, smaller size, and less solid phenotype.
  • [MeSH-major] Adenocarcinoma / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623049.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


51. Sakellaridis T, Mathioulakis S, Antiochos C: Synchronous early primary adenocarcinoma of both rectum and gallbladder. Report of a case. Int Semin Surg Oncol; 2005 Sep 14;2:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous early primary adenocarcinoma of both rectum and gallbladder. Report of a case.
  • BACKGROUND: Synchronous early primary cancers are rare and in addition synchronous adenocarcinoma of both rectum and gallbladder is extremely rare.
  • CASE REPORT: We report an unusual case of synchronous early primary adenocarcinoma of rectum and gallbladder.
  • An endoscopy revealed adenocarcinoma of the lower rectum.
  • The histopathological diagnosis was well to middle differentiate adenocarcinoma of the gallbladder (T2, N0, M0; stage II) and middle differentiate adenocarcinoma of the rectum (T2, N0, M0; stage II).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2001 Jan-Feb;53(1):133-9 [11280822.001]
  • [Cites] Asian J Surg. 2003 Jan;26(1):46-8; discussion 49 [12527496.001]
  • [Cites] Jpn J Cancer Res. 1987 Mar;78(3):242-50 [3106280.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jun;94(6):440-4 [9216227.001]
  • [Cites] Gan No Rinsho. 1985 Nov;31(14):1849-53 [4087393.001]
  • [Cites] Srp Arh Celok Lek. 1965 Mar;93(3):323-7 [5861499.001]
  • [Cites] Ann Surg. 1982 Apr;195(4):501-7 [7065754.001]
  • [Cites] Klin Wochenschr. 1988 Nov 1;66(21):1093-6 [3236758.001]
  • (PMID = 16162293.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1236954
  •  go-up   go-down


52. Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, Ouellette MM: Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology; 2007 Oct;51(4):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
  • Pancreatic ductal adenocarcinomas show limited responsiveness to taxanes, but little is known of the underlying mechanisms.
  • The aim of this study was to examine TUBB3 expression in pancreatic cancer cell lines, invasive pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).
  • Immunohistochemistry was employed to assess TUBB3 in pancreatic cancer specimens, including 75 invasive adenocarcinomas and 41 PanIN precursor lesions.
  • In contrast, the vast majority (78-93%) of pancreatic ductal adenocarcinomas demonstrated either diffuse or focal TUBB3 expression.
  • CONCLUSIONS: TUBB3 is expressed in most pancreatic ductal adenocarcinomas, possibly accounting for the suboptimal response of these tumours to microtubule-stabilizing agents.
  • Up-regulation of TUBB3 in PanIN lesions suggests that microtubule dysfunction is an early feature of this disease.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma in Situ / metabolism. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Pancreatic Neoplasms / metabolism. Tubulin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714470.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / TUBB3 protein, human; 0 / Tubulin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


53. Ashton-Sager A, Paulino AF, Afify AM: GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
  • Although the aberrant expression of GLUT-1 has been reported in a wide spectrum of epithelial malignancies, its possible correlation with the malignant transformation of endometrial epithelium has not been clearly established.
  • The purpose of this study was to evaluate the extent to which benign, hyperplastic, atypical, and malignant endometrial epithelia express GLUT-1.
  • The authors examined the IHC expression of GLUT-1 in cases of proliferative endometrium (n=12), secretory endometrium (n=10), endometrial polyps (n=10), adenomyosis (n=18), simple hyperplasia (n=14), complex hyperplasia without atypia (n=17), complex hyperplasia with atypia (n=17), and adenocarcinoma (n=31).
  • GLUT-1 was expressed in 24% (4/17 cases) of complex hyperplasia without atypia, 71% (12/17 cases) of complex hyperplasia with atypia, and 90% (28/31 cases) of adenocarcinomas.
  • The authors conclude that GLUT-1 is preferentially expressed in complex hyperplasia with atypia and in adenocarcinoma and that GLUT-1 immunostaining is useful in distinguishing benign hyperplasia from hyperplasia strongly associated with malignancy.
  • These data suggest that the expression of GLUT-1 transporter may be closely related to the malignant transformation of epithelial endometrial tumors by supporting their increased need for glucose metabolism.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785788.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1
  •  go-up   go-down


54. Morita T: Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient. Int Med Case Rep J; 2010;3:39-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23754886.001).
  • [ISSN] 1179-142X
  • [Journal-full-title] International medical case reports journal
  • [ISO-abbreviation] Int Med Case Rep J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3658217
  • [Keywords] NOTNLM ; estramustine phosphate / hormone-refractory prostate cancer / leukocytosis / neutrophilia
  •  go-up   go-down


55. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med; 2007 Oct;131(10):1561-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
  • CONTEXT: Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult.
  • OBJECTIVE: To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin.
  • DESIGN: Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels.
  • Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method.
  • Results were validated using 60 cases of metastatic adenocarcinoma with known primaries.
  • RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.
  • Overall, these combined phenotypes correctly predicted the tester samples (metastatic adenocarcinomas with known primaries) in 75% of cases.
  • CONCLUSIONS: Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Neoplasm Proteins / analysis
  • [MeSH-minor] Decision Trees. Female. Humans. Neoplasms, Unknown Primary / chemistry. Neoplasms, Unknown Primary / diagnosis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922593.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


56. Koshiyama M, Kinezaki M, Uchida T, Sumitomo M: Chemosensitivity testing of paclitaxel versus docetaxel in human gynecological carcinomas: a comparison with carboplatin. Anticancer Res; 2006 Sep-Oct;26(5B):3655-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, the I.R. for paclitaxel was significantly higher than docetaxel [83.0% vs. 62.9% (p < 0.05)] in serous adenocarcinomas.
  • In clear cell adenocarcinomas, however, both the I.R.s for paclitaxel and docetaxel were significantly lower than carboplatin [27.8% and 23.3% vs. 58.5%, respectively (p < 0.01)].
  • Furthermore, the I.R. for docetaxel was significantly lower in G2 and G3 adenocarcinomas [16.9% vs. 45.8% and 52.8% (p < 0.05, p < 0.01, respectively)] [16.5% vs. 46.2% and 53.2% (p < 0.01, p < 0.001, respectively)].

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094381.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 0 / Tetrazolium Salts; 0 / Thiazoles; 15H5577CQD / docetaxel; 298-93-1 / thiazolyl blue; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


57. Doggui MH, Ben Yaghlène L, Hefaiedh R, Bouguassas W, Mestiri A, Dellagi K: A gastric collision tumor composed of adenocarcinoma and gastrinoma: case report. Tunis Med; 2008 Aug;86(8):755-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastric collision tumor composed of adenocarcinoma and gastrinoma: case report.
  • BACKGROUND: Collision tumors of the stomach are exceedingly rare, with only six previous reported instance in which adenocarcinoma of the stomach were found in association with carcinoid tumor.
  • Only in one case the adenocarcinoma was associated with a gastrinoma.
  • AIM: we report the second case of Collision tumor between adenocarcinoma and gastrinoma.
  • The pathologic examination of the biopsy specimen of the process revealed an adenocarcinoma and of the polypoid tumors showed a carcinoid type tumor.
  • The diagnosis of collision type tumors between adenocarcinoma and gastrinoma was retained.
  • CONCLUSION: Through this observation and with a review of literature, the coexistence of adenocarcinoma and carcinoid tumor of the stomach is discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrinoma / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472762.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


58. D'Onofrio M, Zamboni GA, Malagò R, Mantovani W, Principe F, Gallotti A, Faccioli N, Falconi M, Capelli P, Mucelli RP: Resectable pancreatic adenocarcinoma: is the enhancement pattern at contrast-enhanced ultrasonography a pre-operative prognostic factor? Ultrasound Med Biol; 2009 Dec;35(12):1929-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable pancreatic adenocarcinoma: is the enhancement pattern at contrast-enhanced ultrasonography a pre-operative prognostic factor?
  • The aim of our study was to determine whether the enhancement pattern of pancreatic adenocarcinoma at contrast-enhanced ultrasonography (CEUS) is related to patient prognosis after resection.
  • CEUS of 42 resected adenocarcinomas were retrospectively reviewed.
  • There were 30 differentiated and 12 undifferentiated adenocarcinomas at pathology.
  • In conclusion, CEUS enables accurate depiction of the vascularization of adenocarcinoma, with positive correlation to histology grade and MVD.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / ultrasonography. Pancreatectomy / mortality. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / ultrasonography. Ultrasonography / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19828234.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


59. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y: Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol; 2007 Jul;128(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
  • Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains unclear whether bronchioloalveolar carcinoma (BAC) components and/or subtypes affect these associations.
  • We examined 141 non-small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12 of the K-ras gene using loop-hybrid mobility shift assays, a highly sensitive polymerase chain reaction-based method.
  • Adenocarcinomas were subdivided into subtypes with a nonmucinous or mucinous BAC component and those without BAC components.
  • In NSCLCs, EGFR mutations were detected in 75 cases (53.2%) and were significantly associated with adenocarcinoma, female sex, and never smoking.
  • Among adenocarcinomas, nonmucinous and mucinous BAC components were significantly associated with EGFR and K-ras gene mutations, respectively.
  • Because EGFR mutations were detected even in most pure nonmucinous BACs, ie, lung adenocarcinoma in situ, EGFR mutation is considered a critical event in the pathogenesis of nonmucinous BAC tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580276.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


60. Götz R: Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. Cancer Cell Int; 2008;8:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutational activation of protein kinases and loss of cell adhesion occur together in human lung adenocarcinoma but how these two pathways interconnect is only poorly understood.
  • Mouse models of human lung adenocarcinoma with oncogene expression targeted to subtypes of lung epithelial cells led to formation of adenomas or adenocarcinomas that lacked metastatic potential.
  • Conditional genetic abrogation of epithelial tumour cell adhesion in mice with benign lung tumours induced by oncogenic RAF kinase has been demonstrated to induce intratumourous vascularization (angiogenic switch), progression to invasive adenocarcinoma and micrometastasis.
  • I will discuss potential routes to nuclear beta-catenin signalling in cancer and how nuclear beta-catenin may epigenetically alter the plasticity of tumour cells during malignant progression.

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1858-62 [8127895.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Dev Biol. 1993 Apr;156(2):426-43 [8462742.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):883-9 [8806677.001]
  • [Cites] Histol Histopathol. 1996 Apr;11(2):463-83 [8861769.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1521-6 [9118033.001]
  • [Cites] Cell. 1997 Sep 5;90(5):871-82 [9298899.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6166-70 [9497337.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1021-6 [9500465.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5762-70 [9742093.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):687-99 [10037790.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):60-71 [10208743.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):406-11 [10425198.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36734-40 [10593980.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):185-90 [10775035.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):813-8 [11259097.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20436-43 [11279024.001]
  • [Cites] Cell. 2001 May 4;105(3):391-402 [11348595.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):768-76 [16084946.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e313 [16187797.001]
  • [Cites] Curr Biol. 2005 Nov 22;15(22):1989-97 [16303557.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):729-39 [16332724.001]
  • [Cites] Immunity. 2005 Dec;23(6):599-609 [16356858.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2279-86 [16489032.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Genome Res. 2006 May;16(5):595-605 [16606705.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):606-13 [16699315.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Development. 2006 Jul;133(13):2455-65 [16735479.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2261-71 [16894562.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Methods Enzymol. 2006;419:285-321 [17141060.001]
  • [Cites] Genes Dev. 2007 Feb 15;21(4):379-84 [17299132.001]
  • [Cites] Cell. 2007 Feb 23;128(4):735-45 [17320510.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Nat Rev Genet. 2007 May;8(5):341-52 [17440531.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1006-13 [17459054.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4933-9 [17510423.001]
  • [Cites] Cell. 2007 Jun 1;129(5):957-68 [17540175.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):318-24 [17554336.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):445-51 [17597761.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):260-2 [17637646.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Arch Toxicol. 1991;65(2):81-94 [1711838.001]
  • [Cites] Exp Cell Res. 1967 Apr;46(1):144-54 [6025276.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):461-71 [7542250.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4553-61 [7623846.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Mar 28;208(3):1067-72 [7702605.001]
  • [Cites] Cell Adhes Commun. 1994 Aug;2(4):319-27 [7820535.001]
  • [Cites] J Cell Biol. 1994 Dec;127(5):1375-80 [7962096.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 30;205(1):73-8 [7999105.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Cell Biol Int. 2007 Apr;31(4):366-73 [17336101.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3113-21 [17496910.001]
  • [Cites] J Pathol. 2007 Jul;212(3):287-94 [17534846.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):313-7 [17554338.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):145-59 [17692806.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):101-6 [18059259.001]
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):147-58 [18246411.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):547-53 [11709274.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Mech Dev. 2002 Jul;115(1-2):53-62 [12049767.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):173-82 [12107102.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6297-303 [12414660.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1333-8 [12423687.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):97S-104S [12527569.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2287-97 [12640114.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2268-77 [12727849.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):118-32 [14964308.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] J Cell Sci. 2004 Jul 1;117(Pt 15):3207-19 [15226396.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):339-49 [15492040.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] APMIS. 2005 Jan;113(1):54-7 [15676015.001]
  • [Cites] Development. 2005 Mar;132(6):1363-74 [15716345.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):45-51 [18196970.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):55-70 [18371336.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Annu Rev Physiol. 2004;66:601-23 [14977415.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] J Biol. 2004;3(3):11 [15186480.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2225-30 [15371335.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):639-47 [15519853.001]
  • [Cites] Cell Res. 2005 Jan;15(1):28-32 [15686623.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9719-26 [16266992.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Cell. 2005 Dec 2;123(5):903-15 [16325583.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):283-9 [16397241.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):399-410 [16481469.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Development. 2006 May;133(9):1611-24 [16613830.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1394-404 [16751178.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 [17052169.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • (PMID = 18492263.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2427011
  •  go-up   go-down


61. Riener MO, Pilarsky C, Gerhardt J, Grützmann R, Fritzsche FR, Bahra M, Weichert W, Kristiansen G: Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma. Histol Histopathol; 2009 09;24(9):1121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.
  • BACKGROUND/AIMS: The human Anterior Gradient-2 (AGR2) is strongly upregulated in various human cancers, including pancreatic ductal adenocarcinomas (PDAC), but its prognostic value in PDAC has not yet been studied.
  • CONCLUSION: Although a prognostic value of AGR2 seems unlikely, further studies are warranted to investigate the biological role of AGR2 in pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Proteins / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609859.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proteins; 0 / RNA, Messenger; EC 5.3.4.1 / AGR2 protein, human
  •  go-up   go-down


62. Layke JC, Lopez PP: Esophageal cancer: a review and update. Am Fam Physician; 2006 Jun 15;73(12):2187-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although significant advancements have been made in the treatment of esophageal cancer, this aggressive malignancy commonly presents as locally advanced disease with a poor prognosis.
  • A clear association has been established between the development of esophageal cancer and Helicobacter pylori infection, gastroesophageal reflux disease, smoking, and heavy alcohol use.
  • However, the growing number of newly diagnosed esophageal adenocarcinomas, despite widespread treatments with proton pump inhibitors and the eradication of H. pylori, leaves the medical community searching for more answers.
  • There is a potential link between esophageal adenocarcinoma and obesity.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836035.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


63. Ueo T, Kashima K, Daa T, Kondo Y, Sasaki A, Yokoyama S: Immunohistochemical analysis of morules in colonic neoplasms: morules are morphologically and qualitatively different from squamous metaplasia. Pathobiology; 2005;72(5):269-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten cases of morule-associated colonic neoplasms (4 adenocarcinomas, 1 adenoma with carcinoma in situ, and 5 adenomas), and 3 cases of squamous metaplasia in colonic adenocarcinoma were examined morphologically and immunohistochemically.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Colonic Neoplasms / pathology. Immunoenzyme Techniques / methods. Precancerous Conditions / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374071.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


64. Molina R, Filella X, Augé JM, Bosch E, Torne A, Pahisa J, Lejarcegui JA, Rovirosa A, Mellado B, Ordi J, Biete A: CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res; 2005 May-Jun;25(3A):1765-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology revealed squamous cancer in 119 patients, adenocarcinoma in 25 patients and adenosquamous carcinoma in the remaining 12 patients.
  • The sensitivity of CYFRA 21.1, CEA and SCC was 26%, 25% and 43%, respectively, at diagnosis.
  • The relationship of CEA with the histological type was poor, but the highest concentrations were found in adenocarcinomas (p=0.034).
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Serpins / blood. Uterine Cervical Neoplasms / blood

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033097.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Serpins; 0 / antigen CYFRA21.1; 0 / squamous cell carcinoma-related antigen; 68238-35-7 / Keratins
  •  go-up   go-down


65. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Cytology of the pleural effusion showed no malignant cells.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology


66. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE: Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol; 2009 Dec 1;100(7):598-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both African Americans and Caucasians, the disease is more common in men.
  • Adenocarcinomas, NOS comprised 65% of all histological types.
  • Papillary carcinomas had a more favorable survival than other types; carcinomas arising in adenomas had a more favorable survival than adenocarcinomas not associated with adenomas.
  • CONCLUSIONS: Prognostic factors include histologic type, grade, stage, and coexisting adenomas.
  • Although certain histologic types exhibit morphologic differences, their pathogenesis appears to be similar.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697352.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract; 2007;203(7):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma.
  • To evaluate the association between the expression of human macrophage metalloelastase (matrix metalloproteinase-12, MMP-12) with cancer invasion and differentiation of endometrial adenocarcinoma, specimens from endometrial adenocarcinoma (n=61) of diverse stages and histologic types were collected from patients having undergone hysterectomy, and specimens from normal endometrium (n=38) were obtained from patients with benign diseases.
  • The positive rate of MMP-12 was significantly increased in endometrial adenocarcinoma (81.97%) as compared with that in normal endometrium (13.16%).
  • MMP-12 immunoreactive proteins were found mainly on the glandular epithelial cells of endometrial adenocarcinoma.
  • The macrophage infiltration detected by CD68 immunohistochemical staining in endometrial adenocarcinoma was also higher than that in normal endometrium.
  • In this study, we show that in addition to macrophages, endometrial adenocarcinoma cells are able to express MMP-12.
  • Increased MMP-12 expression tended to be associated with the extent of adenocarcinoma invasion accompanied by marked macrophage infiltration.
  • Our results suggest that MMP-12 is an important oncogene in high-stage and high-grade endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 12 / biosynthesis. Neoplasm Invasiveness / genetics
  • [MeSH-minor] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Blotting, Western. Female. Gene Expression. Humans. Immunohistochemistry. Macrophages / metabolism. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574772.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


68. Adhya AK, Mahesha V, Srinivasan R, Nijhawan R, Rajwanshi A, Suri V, Dhaliwal LK: Atypical glandular cells in cervical smears: histological correlation and a suggested plan of management based on age of the patient in a low-resource setting. Cytopathology; 2009 Dec;20(6):375-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follow-up histology was normal or benign in 20 cases, whereas a squamous or glandular abnormality was seen in 11 cases.
  • Squamous abnormalities included one case each of cervical intraepithelial neoplasia (CIN)1, CIN2 and CIN3 and five cases of squamous cell carcinoma.
  • All glandular epithelial abnormalities were endometrial in origin and included two endometrial adenocarcinomas and one uterine serous carcinoma.
  • Neither in situ nor invasive adenocarcinoma of the endocervix was observed.
  • Review of smears and reclassification as AGC, not otherwise specified and favour neoplasia revealed a higher proportion of abnormality in the latter group, reaffirming the utility of subtyping.
  • In women aged equal or more than 40 years, AGC reflected a high-grade squamous or glandular epithelial abnormality in 50% of cases compared with none in those less than 40 years old (P = 0.010).
  • CONCLUSION: The age of the woman as well as the subtype of atypical glandular cells influences outcome and hence must be taken into consideration while formulating an acceptable management strategy in these women in a low-resource setting.


69. Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE: FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol; 2008 May-Jun;32(3):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions.
  • The authors examined FAP-alpha and uPA expression in premalignant and malignant stages of esophageal adenocarcinoma by immunohistochemistry.
  • Stromal FAP-alpha expression was associated with depth of tumor invasion, while stromal uPA expression correlated with lymph node metastases in adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / biosynthesis. Biomarkers, Tumor / biosynthesis. Esophageal Neoplasms / metabolism. Precancerous Conditions / metabolism. Serine Endopeptidases / biosynthesis. Urokinase-Type Plasminogen Activator / biosynthesis
  • [MeSH-minor] Barrett Esophagus / metabolism. Barrett Esophagus / pathology. Blotting, Western. Disease Progression. Female. Gelatinases. Gene Expression. Humans. Immunohistochemistry. Male. Membrane Proteins

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570153.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


70. Yue W, Wang Z, Wang Y, Zhang L: [Construction of a t7 human lung cancer cDNA library.]. Zhongguo Fei Ai Za Zhi; 2008 Oct 20;11(5):686-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Currently, only a limited numbers of tumor markers for non small lung cancer (NSCLC) diagnosis, new biomarker, such as serum autoantibody may improve the early detection of lung cancer.
  • Our objective is construction human lung squamous carcinoma and adenocarcinoma T7 phage display cDNA library from the tissues of NSCLC patients.
  • METHODS: mRNA was isolated from a pool of total RNA extract from NSCLC tissues obtained from 5 adenocarcinomas and 5 squamous carcinomas, and then mRNA was reverse transcribed into double stranded cDNA.
  • Plaque assay show the titer of lung squamas carcinoma library was 1.8*10(6) pfu, and the adenocarcinoma library was 5*10(6) pfu.
  • PCR amplification of random plaque show insert ratio were 100% (24/24) in adenocarcinoma library and 95.8% in human lung squamas carcinoma library (23/24).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738913.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Shilo K, Colby TV, Travis WD, Franks TJ: Exuberant type 2 pneumocyte hyperplasia associated with spontaneous pneumothorax: secondary reactive change mimicking adenocarcinoma. Mod Pathol; 2007 Mar;20(3):352-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exuberant type 2 pneumocyte hyperplasia associated with spontaneous pneumothorax: secondary reactive change mimicking adenocarcinoma.
  • In addition to reactive eosinophilic pleuritis, subpleural emphysematous blebs, prominent eosinophilic exudate and lung atelectasis, the histology comprised exuberant type 2 pneumocyte hyperplasia, which was atypical enough to consider a diagnosis of adenocarcinoma in all four cases.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelial Cells / pathology. Pneumothorax / complications. Pneumothorax / pathology
  • [MeSH-minor] Adult. Blister / etiology. Blister / pathology. Diagnosis, Differential. Eosinophils. Humans. Hyperplasia. Male. Pleurisy / etiology. Pleurisy / pathology. Pulmonary Atelectasis / etiology. Pulmonary Atelectasis / pathology

  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277763.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Ishihara T, Takeuchi T, Nishimori I, Adachi Y, Minakuchi T, Fujita J, Sonobe H, Ohtsuki Y, Onishi S: Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma. Virchows Arch; 2006 Jun;448(6):830-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
  • In the present study, we examined ultrastructural changes caused by exogenous CA-RP VIII expression in a well-differentiated lung adenocarcinoma cell line, PC-9.
  • We subsequently examined CA-RP VIII expression in atypical adenomatous hyperplasia and early-stage lung adenocarcinoma (Stage Ia).
  • Significant expression of CA-RP VIII was observed in invasive lung adenocarcinoma but not in noninvasive adenocarcinoma.
  • Interestingly, CA-RP VIII was strongly expressed in signet-ring cell cancer and invasive mucinous adenocarcinoma components.
  • The present findings suggest that CA-RP VIII expression in lung adenocarcinoma is related to cancer cell invasion.
  • [MeSH-minor] Adenoma / genetics. Adenoma / ultrastructure. Biomarkers, Tumor. Cell Line, Tumor. Cell Movement. Gene Expression. Humans. Hyperplasia. Immunohistochemistry. Microscopy, Electron, Transmission. Mucins / metabolism. Neoplasm Invasiveness. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Vacuoles / ultrastructure

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):663-72 [11159203.001]
  • [Cites] Neuroscience. 2002;112(1):93-9 [12044474.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):442-52 [15087663.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5537-44 [12944900.001]
  • [Cites] Virchows Arch. 2003 Jan;442(1):66-70 [12536316.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):189-93 [9630625.001]
  • [Cites] J Pathol. 2003 Sep;201(1):37-45 [12950015.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17213-20 [11279065.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1489-97 [10737605.001]
  • [Cites] J Pathol. 1988 Sep;156(1):23-7 [3057151.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):868-74 [15223955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4874-9 [10220386.001]
  • [Cites] Ann Rheum Dis. 2003 Mar;62(3):196-203 [12594102.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):273-80 [15140539.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):806-13 [8077365.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):435-41 [12611586.001]
  • [Cites] J Biol Chem. 1990 Apr 5;265(10):5573-8 [2318825.001]
  • [Cites] FEBS Lett. 1990 Oct 1;271(1-2):137-40 [2121526.001]
  • (PMID = 16609906.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA8 protein, human; 0 / Car8 protein, mouse; 0 / Mucins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


73. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • This finding suggests that PR expression is not directly involved in neoplastic transformation of the endometrium and that such expression is not a prognostic indicator.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • The proliferation index as determined by Ki-67 expression was 9.7+/-2.75% (mean+/- standard-deviation (SD)) for normal endometrium, 11.29+/-2.5% for hyperplastic endometrium, 19.40+/-3.01% for benign tumours and 19.41+/-7.9% for malignant tumours.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


74. Reddy VB, Aslanian H, Suh N, Longo WE: Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease. World J Gastroenterol; 2008 Aug 7;14(29):4690-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease.
  • A 53-year old previously healthy male underwent a screening colonoscopy for detection of a potential colorectal neoplasm.
  • The biopsy of the ileal mass was consistent with an adenocarcinoma arising from the terminal ileum.
  • His father who had never been previously ill from gastrointestinal disease died of natural causes, but was found to have Crohn's disease postmortem.
  • Findings were consistent with ileal adenocarcinoma in the setting of Crohn's disease.
  • The pathology was stage 1 adenocarcinoma.
  • This is a unique case in that on a screening colonoscopy, a favorable ileal adenocarcinoma was discovered in the setting of asymptomatic, undiagnosed ileal Crohn's disease in a patient whose father had Crohn's disease diagnosed postmortem.
  • [MeSH-major] Adenocarcinoma / diagnosis. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] J Clin Gastroenterol. 1984 Jun;6(3):217-24 [6327804.001]
  • [Cites] World J Surg. 1985 Dec;9(6):914-20 [4082613.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):360-3 [2910443.001]
  • [Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1444-51 [1358741.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Nov;14(11):1132-4 [10574144.001]
  • [Cites] Clin Imaging. 1999 Sep-Oct;23(5):298-301 [10665347.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Scand J Gastroenterol. 2001 Jun;36(6):641-6 [11424324.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10 [12169995.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Australas Radiol. 2003 Dec;47(4):450-2 [14641202.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):1009-14 [14648412.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):106-16 [14716243.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):778-81 [15037927.001]
  • [Cites] Radiographics. 2004 May-Jun;24(3):689-702 [15143222.001]
  • [Cites] Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S32-4 [15168828.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7 [15181618.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2585-7 [15300912.001]
  • [Cites] Gastroenterol Nurs. 2004 Jul-Aug;27(4):170-5 [15326402.001]
  • [Cites] Lancet. 1973 Jan 6;1(7793):24-6 [4118541.001]
  • [Cites] Gut. 1973 Feb;14(2):120-4 [4696534.001]
  • [Cites] Am J Dig Dis. 1973 Dec;18(12):1095-8 [4761532.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Cancer. 1976 Jun;37(6):2948-59 [949714.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Gut. 1982 Mar;23(3):188-93 [7040175.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Med Clin North Am. 1994 Nov;78(6):1399-412 [7967916.001]
  • [Cites] Gut. 1994 Nov;35(11):1507-8 [7828962.001]
  • [Cites] Am J Gastroenterol. 1996 Mar;91(3):434-40 [8633487.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1315-21 [8918446.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):275-84 [9500769.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 May;10(5):431-2 [9619392.001]
  • [Cites] Surgery. 1956 Feb;39(2):347-51 [13298987.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5 [12950413.001]
  • (PMID = 18698685.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738795
  •  go-up   go-down


75. Fujimori S, Ehara A, Seo T, Mitsui K, Sakamoto C: [Primary small intestinal malignant tumors]. Nihon Rinsho; 2008 Jul;66(7):1286-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary small intestinal malignant tumors].
  • Small intestinal primary adenocarcinomas, carcinoids, gastrointestinal stromal tumors (GISTs) were cleared up inadequately because it was hard to examine for small intestine by modalities in the 20th century.
  • We attempt to present these small intestinal malignant tumors using by capsule endoscopy and double balloon endoscopy.
  • [MeSH-major] Adenocarcinoma. Carcinoid Tumor. Gastrointestinal Stromal Tumors. Intestinal Neoplasms. Intestine, Small

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616119.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 30
  •  go-up   go-down


76. Frederiksen BL, Osler M, Harling H, Ladelund S, Jørgensen T: Do patient characteristics, disease, or treatment explain social inequality in survival from colorectal cancer? Soc Sci Med; 2009 Oct;69(7):1107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do patient characteristics, disease, or treatment explain social inequality in survival from colorectal cancer?
  • This paper investigates the association between individually measured socioeconomic status (SES) and all-cause survival in colorectal cancer patients, and explores whether factors related to the patient, the disease, or the surgical treatment mediate the observed social gradient.
  • The data were derived from a nationwide clinical database of all adenocarcinomas of the colon or rectum diagnosed in Denmark between 2001 and 2004 (inclusive).
  • A series of regression analyses were used to test potential mediators of the association between the socioeconomic indicators and survival by stepwise inclusion of lifestyle factors (smoking, alcohol intake, body mass index), comorbidity, stage of disease, mode of admission, type of operation, specialization of the surgeon, and curative versus palliative resection.
  • Inclusion of comorbidity, and to a lesser extent lifestyle, reduced the variation associated with SES, while no evidence of a mediating effect was found for disease or surgical treatment factors.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality. Health Status Disparities. Social Class. Survivors / statistics & numerical data
  • [MeSH-minor] Aged. Comorbidity. Databases, Factual. Denmark / epidemiology. Female. Humans. Life Style. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Regression Analysis. Risk Factors. Socioeconomic Factors


77. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med; 2008 May;37(5):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
  • BACKGROUND: Recent studies have proposed that minichromosome maintenance (Mcm) proteins may be sensitive proliferation markers and may serve as novel biomarkers for prognostication and diagnosis of various pre-malignant and malignant lesions.
  • The aims of this study were to determine the expression of Mcm-2, Ki-67 and geminin in salivary gland (SG) tumours, and to evaluate their usefulness for diagnosis or for prediction of tumour behaviour.
  • There were 13 adenoid cystic carcinomas (ACC), 10 carcinoma ex pleomorphic adenomas (CEPA), 10 mucoepidermoid carcinomas (MEC), 10 polymorphous low-grade adenocarcinomas (PLGA), 10 pleomorphic adenomas (PA) and nine acinic cell carcinomas (AcCC).
  • CONCLUSIONS: The findings suggest that Mcm-2 may be a sensitive proliferation marker in SG tumours and may be useful for differential diagnosis between PA and CEPA, and ACC and PLGA.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Geminin. Humans. Immunoenzyme Techniques. Male. Microarray Analysis. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248354.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


78. Le Leu RK, Brown IL, Hu Y, Esterman A, Young GP: Suppression of azoxymethane-induced colon cancer development in rats by dietary resistant starch. Cancer Biol Ther; 2007 Oct;6(10):1621-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Feeding resistant starch significantly reduced the incidence (p < 0.01) and multiplicity (p < 0.05) of adenocarcinomas in the colon compared to the Control diet.

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17932462.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Dietary Carbohydrates; 0 / Fatty Acids, Volatile; 0 / Proliferating Cell Nuclear Antigen; 9005-25-8 / Starch; 9005-82-7 / Amylose; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


79. Kim KR, Lee HI, Lee SK, Ro JY, Robboy SJ: Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion? Am J Surg Pathol; 2007 Apr;31(4):546-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine whether stromal microinvasion can be distinguishable from extruded neoplastic epithelium from an adjacent ruptured gland, particularly if accompanied by a mucin granuloma (MG) on hematoxylin and eosin (H&E)-stained sections, we compared the histopathologic features of 138 primary ovarian mucinous tumors, consisting of 81 MBTs, 37 MBTs with stromal microinvasion, 11 intraglandular carcinomas, 2 with microinvasive foci, and 7 mucinous adenocarcinomas with extensive stromal invasion.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Neoplasm Metastasis / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414101.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Hervieu V, Scoazec JY: [Mixed endocrine tumors]. Ann Pathol; 2005 Dec;25(6):511-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of their rarity and unusual presentation, endocrine mixed tumors raise many problems of diagnosis, management and therapy.
  • In some cases, the endocrine component is poorly differentiated: the demonstration of neuro-endocrine markers is necessary to confirm the diagnosis.
  • Mixed tumors containing a well differentiated endocrine component and an adenocarcinomatous component are to be treated like adenocarcinomas.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735976.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 128
  •  go-up   go-down


81. Petty RD, Kerr KM, Murray GI, Nicolson MC, Rooney PH, Bissett D, Collie-Duguid ES: Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol; 2006 Apr 10;24(11):1729-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High SerpinB3 expression levels, invariably associated with chemoresistance, had contrasting prognostic impact in untreated squamous cell carcinomas (hazard ratio [HR], 0.43; 95% CI, 0.18 to 0.93) or adenocarcinomas (HR, 2.09; 95% CI, 1.03 to 4.72).


82. Kidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, Zikusoka MN: Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer; 2006 Apr 1;106(7):1480-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of molecular genetic signatures in the delineation of gastric neoplasia.
  • BACKGROUND: Current techniques to define gastric neoplasia are limited but molecular genetic signatures can categorize tumors and provide biological rationale for predicting clinical behavior.
  • We identified three gene signatures: Chromogranin A (CgA), MAGE-D2 (adhesion), and MTA1 (metastasis) that define gastrointestinal (GI) carcinoids and hypothesize that their expression can delineate gastric neoplasia.
  • This strategy provides a molecular basis to define neuroendocrine gastric carcinoids (GCs), neuronal stromal tumors (GISTs), or epithelial cell (gastric adenocarcinomas [GCAs])-derived tumors.
  • Quantitative reverse transcriptase polymerase chain reaction (Q RT-PCR) gene expression was quantified against glyseraldehyde-3-phosphate dehydrogenase (GAPDH) and CgA and MTA1 protein expression levels were analyzed by immunohistochemical analyses of a gastric neoplasia microarray.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Carcinoid Tumor / genetics. Chromogranins / genetics. Histone Deacetylases / genetics. Repressor Proteins / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Chromogranin A. Diagnosis, Differential. Female. Gene Expression Profiling. Genetic Markers. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Phenotype. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16502410.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-097050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Chromogranin A; 0 / Chromogranins; 0 / Genetic Markers; 0 / MAGED2 protein, human; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


83. Fischer HP: [Regression and therapy-resistance of primary liver tumors and liver metastases after regional chemotherapy and local tumor ablation]. Pathologe; 2005 May;26(3):191-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In carcinomas with an infiltrating border, especially in metastases of adenocarcinomas and hepatic cholangiocarcinoma cytostatic treatment damages the tumor tissue mainly in the periphery.
  • [MeSH-minor] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Combined Modality Therapy. Embolization, Therapeutic. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 May 1;73(9):2259-67 [7513245.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):480-5 [11379338.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):519-22 [12749262.001]
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):387-92 [6329503.001]
  • [Cites] Acta Pathol Microbiol Scand. 1967;71(2):179-86 [4966497.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;405(2):277-84 [3918391.001]
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):59-65 [11154173.001]
  • [Cites] Pathologe. 1985 Jan;6(1):16-23 [3983083.001]
  • [Cites] J Magn Reson Imaging. 2003 Jun;17(6):663-70 [12766895.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1184-91 [2417696.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):172-82 [12115331.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):62-5 [8380123.001]
  • [Cites] Cancer J. 2004 Mar-Apr;10(2):128-38 [15130272.001]
  • [Cites] Hepatology. 1998 Jan;27(1):67-72 [9425919.001]
  • [Cites] Acta Pathol Microbiol Scand. 1967;71(2):187-93 [5582843.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2452-63 [10861420.001]
  • [Cites] Hepatogastroenterology. 1994 Oct;41(5):427-31 [7851850.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):385-91 [1845943.001]
  • [Cites] Acad Radiol. 2004 Feb;11(2):215-23 [14974597.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):81-6 [1845939.001]
  • [Cites] Hepatogastroenterology. 1998 Aug;45 Suppl 3:1254-8 [9730384.001]
  • [Cites] Dig Surg. 1998;15(6):674-8 [9845635.001]
  • (PMID = 15756550.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


84. Geng W, Wang Z, Zhang J, Reed BY, Pak CY, Moe OW: Cloning and characterization of the human soluble adenylyl cyclase. Am J Physiol Cell Physiol; 2005 Jun;288(6):C1305-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunoblot analysis showed 190- and 80-kDa bands in multiple human cell lines from gut, renal, and bone origins in both cytosol and membrane fractions, including Caco-2 colorectal adenocarcinomas, HEK-293 cells, HOS cells, and primary human osteoblasts, as well as in vitro induced osteoclast-like cells.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659711.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P01 DK-20543; United States / NIDDK NIH HHS / DK / R01 DK-48481
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bicarbonates; 42Z2K6ZL8P / Manganese; EC 4.6.1.1 / Adenylyl Cyclases; I38ZP9992A / Magnesium
  •  go-up   go-down


85. Kobayashi H, Minami Y, Anami Y, Kondou Y, Iijima T, Kano J, Morishita Y, Tsuta K, Hayashi S, Noguchi M: Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Arch; 2010 Jul;457(1):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma.
  • The aim of this study was to investigate the expression of GA733 gene family members and to compare their prognostic significance in pulmonary adenocarcinoma.
  • One hundred thirty paraffin-embedded specimens of small-sized pulmonary adenocarcinoma, less than 2 cm in diameter, were categorized using the classification of small-sized pulmonary adenocarcinoma devised by Noguchi et al. (Cancer 75:2844-2852, 1995) and examined immunohistochemically using a murine monoclonal antibody against Ep-CAM and a goat polyclonal antibody against TROP2.
  • Ep-CAM and TROP2 were similarly expressed in many small-sized pulmonary adenocarcinomas.
  • The expression of Ep-CAM was significantly related to a favorable outcome (p = 0.0185), whereas TROP2 tended to be expressed in cases with an unfavorable outcome (p = 0.0564), and was significantly associated with an unfavorable outcome in nonlepidic-type adenocarcinomas (p = 0.0125).
  • Although the two GA733 proteins share structural similarity, they appear to have opposite biological significances in small-sized adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / biosynthesis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2004 Aug;86(3):207-13 [15567937.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Oct;40(1):17-24 [11578913.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):483-8 [16678891.001]
  • [Cites] Mol Cell Biol. 1993 Mar;13(3):1507-15 [8382772.001]
  • [Cites] Br J Cancer. 2005 May 9;92 (9):1767-72 [15870832.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10 ):699-712 [10606205.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):420-3 [10192395.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10 (9):3131-6 [15131054.001]
  • [Cites] Cell Adhes Commun. 1994 Oct;2(5):417-28 [7842256.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1290-5 [18813308.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98 (6):883-8 [11948467.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):186-91 [18084248.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):691-7 [9586666.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3057-63 [16707602.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5464-71 [15328185.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):19-24 [10458213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3542-6 [2333300.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):671-6 [9610724.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14 (18):5849-55 [18794096.001]
  • [Cites] BMC Cancer. 2006 Jun 23;6:165 [16796747.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):209-20 [11391791.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):27-31 [2911574.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):221-32 [17361206.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Cancer Sci. 2005 Oct;96(10):668-75 [16232198.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):482-7 [10821496.001]
  • (PMID = 20473768.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule
  •  go-up   go-down


86. Ohike N, Sato M, Kawahara M, Ohyama S, Morohoshi T: Ductal adenocarcinoma of the pancreas with psammomatous calcification. Report of a case. JOP; 2008;9(3):335-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the pancreas with psammomatous calcification. Report of a case.
  • CONTEXT: Calcification is extremely rare in pancreatic ductal adenocarcinomas, but we may sometimes encounter focal dystrophic calcification.
  • CASE REPORT: We herein report the case of an 83-year-old female with pancreatic ductal adenocarcinoma associated with diffuse psammomatous calcification.
  • CONCLUSIONS: The possibility of pancreatic ductal adenocarcinoma should therefore be considered for a localized calcified lesion in the pancreas.
  • Studies to elucidate the prognostic significance of psammoma bodies in pancreatic ductal adenocarcinomas are therefore recommended.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469450.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


87. Shibata T, Noguchi T, Takeno S, Gabbert HE, Ramp U, Kawahara K: Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. Ann Surg Oncol; 2008 Dec;15(12):3579-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas.
  • METHODS: XIAP, Smac/DIABLO, and XAF1 expression was analyzed by immunohistochemistry (IHC) in 187 gastric adenocarcinomas.
  • Disease-specific survival after surgery was examined.
  • Individually, XIAP, Smac, and XAF1 were not significantly associated with disease-specific survival.
  • CONCLUSION: The expression balance of XIAP and XAF1 is an independent prognostic factor in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Mitochondrial Proteins / metabolism. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807090.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XAF1 protein, human; 0 / XIAP protein, human
  •  go-up   go-down


88. Seoane A, Bessa X, Balleste B, O'Callaghan E, Panadès A, Alameda F, Navarro S, Gallén M, Andreu M, Bory F: [Helicobacter pylori and gastric cancer: relationship with histological subtype and tumor location]. Gastroenterol Hepatol; 2005 Feb;28(2):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helicobacter pylori and gastric cancer: relationship with histological subtype and tumor location].
  • [Transliterated title] Helicobacter pylori y cáncer gástrico: relación entre el subtipo histológico y la localización del tumor.
  • INTRODUCTION: Helicobacter pylori (HP) has been implicated in the pathogenesis of gastric adenocarcinoma.
  • Published data on HP infection and its association with both histological subtype and tumor localization are contradictory and few data are available on this topic in Spain.
  • The aim of the present study was to evaluate the association of HP infection with histological subtype and tumor localization in a series of patients with gastric adenocarcinoma.
  • The histological subtype was established using Lauren's classification.
  • RESULTS: During the study period, 304 gastric neoplasms, 275 (90.4%) adenocarcinomas, 22 (7.2%) lymphomas, 3 (1.0%) leiomyosarcomas, 2 (0.7%) degenerated gastrointestinal stromal tumors (GIST) and 2 (0.7%) Kaposi's sarcomas were diagnosed.
  • In patients with adenocarcinoma, the mean age at diagnosis was 69 years and most patients were male (62%).
  • HP infection was confirmed in 69% of the patients (68% in intestinal subtype, 69% in diffuse subtype, and 69% in indeterminate subtype, p = 0.84), and was significantly associated with distal adenocarcinomas vs. proximal adenocarcinomas (73.6% vs 48.6%, p < 0.05).
  • CONCLUSIONS: No differences were observed between the histological type of adenocarcinoma and HP infection.
  • In the last few years, the incidence of fundic adenocarcinomas has increased.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies


89. Arista-Nasr J, Martínez-Mijangos O, Martínez-Benítez B: [Utility of additional histological sections on prostatic needle biopsies with focal glandular atypia]. Actas Urol Esp; 2008 Jun;32(6):594-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Utilidad de los cortes adicionales múltiples en biopsias prostáticas con atipia glandular focal.
  • Although this is a relatively frequent finding, the advantage of carrying out additional sections has not been extensively explored.
  • The additional sections made it possible to establish a definitive diagnosis of malignancy in nine (22.5%) of the 38 cases, because they made more apparent the architectural and cytological features of prostatic carcinoma.
  • CONCLUSIONS: The additional sections are useful for the diagnosis of adenocarcinoma in one of every four or five needle biopsies with focal glandular atypia.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655342.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH: The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol; 2008 Aug;110(2):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Paraffin-embedded tissues from 79 patients with stage I endometrial adenocarcinoma and 12 samples from normal endometrium were analyzed using immunohistochemistry for the detection of FOXP3(+) lymphocytes.
  • CONCLUSIONS: The correlation between the presence of FOXP3(+) Tregs and high vessel density in endometrial adenocarcinomas suggests a link between immunity, intratumoral angiogenesis and poor prognosis.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / immunology. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / immunology. Forkhead Transcription Factors / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Endometrium / immunology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / immunology. Neovascularization, Pathologic / pathology. Receptors, Estrogen / biosynthesis. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533240.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Estrogen
  •  go-up   go-down


91. Kazama Y, Watanabe T, Kanazawa T, Tanaka J, Tanaka T, Nagawa H: Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features. J Clin Pathol; 2007 Jun;60(6):701-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features.
  • BACKGROUND: Poorly differentiated adenocarcinomas of the colon and rectum (Por) feature the worst prognosis among the various types of colorectal carcinomas.
  • This indicates that MSI-Por is a less aggressive subtype.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Microsatellite Instability
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation. DNA, Neoplasm / genetics. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):921-8 [11040179.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2025-37 [11066042.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1166-70 [11861399.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] J Clin Pathol. 2003 May;56(5):327-35 [12719450.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5738-44 [14522894.001]
  • [Cites] J Surg Oncol. 1982 Nov;21(3):143-8 [7132366.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):803-10 [6499620.001]
  • [Cites] Dis Colon Rectum. 1987 Dec;30(12):934-8 [3691264.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):33-8 [9988229.001]
  • [Cites] Ann Surg Oncol. 2000 May;7(4):276-80 [10819367.001]
  • (PMID = 17557871.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1955052
  •  go-up   go-down


92. Schwarz J, Ayim A, Schmidt A, Jäger S, Koch S, Baumann R, Dünne AA, Moll R: Differential expression of desmosomal plakophilins in various types of carcinomas: correlation with cell type and differentiation. Hum Pathol; 2006 May;37(5):613-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have performed a systematic immunohistochemical study of the 3 PKPs in oral and pharyngeal squamous cell carcinomas (SqCCs; n = 40); colorectal, pancreatic, and prostate adenocarcinomas (n = 31), and hepatocellular carcinomas (HCCs; n = 8).
  • In contrast, all adenocarcinomas contained PKP 2 and-often abundantly-PKP 3 in desmosome-typical pattern, whereas PKP 1 was expressed only in prostate tumors.
  • The presence of PKP 3 in adenocarcinomas was confirmed by immunoblotting.
  • For PKP 1, a suppressor function of malignant behavior seems conceivable, whereas the putative functional significance of its occurrence in tumor cell nuclei requires further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Desmosomes / metabolism. Neoplasms / metabolism. Plakophilins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647960.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plakophilins
  •  go-up   go-down


93. Allard JE, Risinger JI, Morrison C, Young G, Rose GS, Fowler J, Berchuck A, Maxwell GL: Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol; 2007 Oct;107(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
  • METHODS: A tissue microarray (TMA) comprised of primary tumor specimens from 485 patients diagnosed with endometrial adenocarcinoma was used to identify cases characterized by FOLR1 overexpression.
  • A shorter progression-free survival was noted in patients with FOLR1 overexpression (log-rank p=0.016) that persisted when the data were limited to patients with stage III/IV disease (log-rank p=0.021) or serous tumors (log-rank p=0.020).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carrier Proteins / metabolism. Disease-Free Survival. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Receptors, Cell Surface / metabolism. Survival Rate

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582475.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FOLR1 protein, human; 0 / Folate Receptor 1; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  •  go-up   go-down


94. Brønden LB, Eriksen T, Kristensen AT: Oral malignant melanomas and other head and neck neoplasms in Danish dogs--data from the Danish Veterinary Cancer Registry. Acta Vet Scand; 2009;51:54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral malignant melanomas and other head and neck neoplasms in Danish dogs--data from the Danish Veterinary Cancer Registry.
  • In humans oral malignant melanoma (OMM) is extremely rare, but represents a particular challenge since it is highly aggressive as is the canine counterpart, which thus may be of interest as a spontaneous animal model.
  • Also the proportions of benign and malignant neoplasms of different locations in dogs were compared using Fisher's exact test.
  • RESULTS: A total of 1768 cases of neoplasias (679 malignant, 826 benign, 263 unknown) were submitted.
  • Of these, 64 (50%) were malignant and 44 (34%) benign.
  • The most common types of malignant neoplasia were SCC (18; 28% of malignant), OMM (13; 20% of malignant), soft tissue sarcoma (11; 17% of malignant) and adenocarcinoma (5; 11% of malignant).
  • The most common types of benign neoplasms were adenoma (7; 16% of benign), polyps (6; 14% of benign) and fibroma (5; 11% of benign).
  • CONCLUSIONS: In the current study, the proportion of neoplasia in the head and neck region in dogs in Denmark was similar to other canine studies and significantly more common than in humans with a large proportion of malignancies.
  • [MeSH-minor] Animals. Denmark / epidemiology. Disease Models, Animal. Dogs. Incidence

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vet Pathol. 2000 Nov;37(6):597-608 [11105949.001]
  • [Cites] Vet Comp Oncol. 2009 Sep;7(3):207-11 [19691649.001]
  • [Cites] Lancet Oncol. 2001 Apr;2(4):205-11 [11905765.001]
  • [Cites] Prev Vet Med. 2003 Apr 30;58(1-2):63-74 [12628771.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1284-90 [12684396.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Oct;61(10):1132-9 [14586846.001]
  • [Cites] J Natl Cancer Inst. 1968 Feb;40(2):307-18 [5694272.001]
  • [Cites] Arch Environ Health. 1971 Jan;22(1):136-40 [4322006.001]
  • [Cites] Eur J Cancer. 1978 Dec;14(12):1299-308 [367792.001]
  • [Cites] Vet Hum Toxicol. 1979 Aug;21(4):277-84 [91256.001]
  • [Cites] Am J Epidemiol. 1981 Aug;114(2):229-33 [7304557.001]
  • [Cites] Onderstepoort J Vet Res. 1983 Sep;50(3):199-220 [6646663.001]
  • [Cites] Vet Rec. 1984 Apr 7;114(14):341-2 [6719788.001]
  • [Cites] Acta Vet Scand Suppl. 1988;84:290-2 [3232625.001]
  • [Cites] J Toxicol Environ Health. 1989;28(4):407-14 [2593174.001]
  • [Cites] Cancer Metastasis Rev. 1990 Sep;9(2):125-36 [2253312.001]
  • [Cites] Am J Epidemiol. 1992 Feb 1;135(3):234-9 [1546698.001]
  • [Cites] Zentralbl Veterinarmed A. 1992 Jun;39(5):328-41 [1496862.001]
  • [Cites] Tidsskr Nor Laegeforen. 1995 Feb 28;115(6):714-7 [7900133.001]
  • [Cites] Berl Munch Tierarztl Wochenschr. 1996 Aug;109(8):292-303 [9005839.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1997 Jan;27(1):101-13 [9002170.001]
  • [Cites] Mol Med Today. 1997 Jan;3(1):8-11 [9021736.001]
  • [Cites] Vet Rec. 1997 Jul 12;141(2):40-4 [9253830.001]
  • [Cites] Am J Epidemiol. 1998 Mar 1;147(5):488-92 [9525536.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Oral Oncol. 2007 Feb;43(2):116-21 [16931116.001]
  • [Cites] Alcohol Res Health. 2006;29(3):193-8 [17373408.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):55-60 [17591290.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 2007 Nov;37(6):1111-9; vi-ii [17950885.001]
  • [Cites] Can Vet J. 2008 Jan;49(1):71-6 [18320982.001]
  • [Cites] Can Vet J. 2008 May;49(5):509-12 [18512465.001]
  • [Cites] Eur J Cancer Prev. 2008 Aug;17(4):340-4 [18562959.001]
  • [Cites] J Vet Intern Med. 2008 Jul-Aug;22(4):976-84 [18564221.001]
  • [Cites] Head Neck. 2008 Dec;30(12):1543-51 [18704960.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1443-51 [19228745.001]
  • [Cites] Oral Oncol. 2009 Mar;45(3):254-8 [18675580.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • (PMID = 20021647.001).
  • [ISSN] 1751-0147
  • [Journal-full-title] Acta veterinaria Scandinavica
  • [ISO-abbreviation] Acta Vet. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803174
  •  go-up   go-down


95. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto G, Zanovello P: Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer; 2006 Oct 1;119(7):1717-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma.
  • We quantified the expression of survivin, both as mRNA in real-time PCR and protein in immunohistochemistry, in tumor samples of 112 patients with esophageal cancer (56 squamous cell carcinomas and 56 adenocarcinomas).
  • In esophageal adenocarcinoma, survivin expression and pattern of distribution had no prognostic relevance.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16671090.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


96. Kobayashi G, Fujita N, Noda Y, Obana T, Takasawa O: Ultrasonographic findings and natural history of intraductal papillary-mucinous neoplasms of the pancreas. J Med Ultrason (2001); 2008 Sep;35(3):85-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is clear that the prevalence of malignancy is high in the main-duct type of intraductal papillary-mucinous neoplasm (IPMN).
  • Branch-duct IPMNs include several histologic conditions such as carcinoma, adenoma, and hyperplasia.
  • Intraductal papillary adenocarcinoma and papillary adenoma are characterized by papillary protrusions and thick septum-like structures in dilated ducts as delineated by ultrasonography.
  • A solid mass showing a mixedecho pattern in the pancreatic parenchyma is a characteristic finding of invasive types of IPMN.
  • Invasive adenocarcinoma can develop at a pancreatic site different from the area of interest showing cystic changes, with such invasion possibly being multicentric.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1997 Mar;45(3):268-76 [9087833.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1996-2000 [9951853.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1993 Dec;90(12):3081-9 [8283821.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 May;91(5):1003-15 [8196194.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):203-8 [9560120.001]
  • [Cites] Eur Radiol. 2001;11(9):1626-30 [11511881.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] J Ultrasound Med. 1997 Jan;16(1):1-6 [8979219.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1807-17 [11745253.001]
  • [Cites] Am J Gastroenterol. 1991 Nov;86(11):1619-25 [1659183.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):962-6 [11490849.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1990 Feb;87(2):235-42 [2157912.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):454-61 [9028354.001]
  • [Cites] Jpn J Cancer Res. 1991 Oct;82(10):1057-60 [1955373.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000 [13362715.001]
  • [Cites] Radiology. 1998 Jul;208(1):231-7 [9646818.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):205-9 [12556785.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):692-709 [8799417.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • (PMID = 27278830.001).
  • [ISSN] 1346-4523
  • [Journal-full-title] Journal of medical ultrasonics (2001)
  • [ISO-abbreviation] J Med Ultrason (2001)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; doubling time / endoscopic ultrasonography (EUS) / intraductal papillary-mucinous neoplasm (IPMN) / natural history
  •  go-up   go-down


97. Wiech T, Nikolopoulos E, Weis R, Langer R, Bartholomé K, Timmer J, Walch AK, Höfler H, Werner M: Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest; 2009 Apr;89(4):385-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays.
  • We performed genome-wide analysis of copy-number changes and loss of heterozygosity (LOH) in Barrett's esophageal adenocarcinoma by single nucleotide polymorphism (SNP) microarrays to identify associated genomic alterations.
  • DNA from 27 esophageal adenocarcinomas and 14 matching normal tissues was subjected to SNP microarrays.
  • Previously described genomic alterations in esophageal adenocarcinomas could be confirmed by SNP microarrays, such as amplification on 8q (CMYC, confirmed by FISH) and 20q13 or deletion/LOH on 3p (FHIT) and 9p (CDKN2A).
  • Using this technique, we identified several novel genes and DNA regions associated with esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Polymorphism, Single Nucleotide

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663352.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Berrar D, Sturgeon B, Bradbury I, Downes CS, Dubitzky W: Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors. J Comput Biol; 2005 Jun;12(5):534-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors.
  • We demonstrate the application of survival trees in a study involving the expression profiles of 3,588 genes in 211 lung adenocarcinoma patients.
  • For both groups, the tree identified characteristic expression profiles of genes that might play a role in cancerogenesis and disease progression, notably the genes for the netrin receptor neogenin and the Ras/Rho kinase modulator diacylglycerol kinase alpha.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Diacylglycerol Kinase / biosynthesis. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Membrane Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952876.001).
  • [ISSN] 1066-5277
  • [Journal-full-title] Journal of computational biology : a journal of computational molecular cell biology
  • [ISO-abbreviation] J. Comput. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / neogenin; EC 2.7.1.107 / Diacylglycerol Kinase
  •  go-up   go-down


99. Ougolkov AV, Bilim VN, Billadeau DD: Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res; 2008 Nov 1;14(21):6790-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We detected nuclear overexpression of EZH2 in pancreatic cancer cell lines and in 71 of 104 (68%) cases of human pancreatic adenocarcinomas.
  • EZH2 nuclear accumulation was more frequent in poorly differentiated pancreatic adenocarcinomas (31 of 34 cases; P<0.001).
  • CONCLUSIONS: Our results show nuclear accumulation of EZH2 as a hallmark of poorly differentiated pancreatic adenocarcinoma; identify the tumor suppressor p27(Kip1) as a new target gene of EZH2; show that EZH2 nuclear overexpression contributes to pancreatic cancer cell proliferation; and suggest EZH2 as a potential therapeutic target for the treatment of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2000 Oct;21(3):226-30 [11039465.001]
  • [Cites] Eur J Hum Genet. 2000 Mar;8(3):174-80 [10780782.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):25-8 [12150822.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] J Exp Med. 2004 Feb 2;199(3):429-34 [14757747.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1161-70 [15292388.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5280-3 [7923154.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] Nat Med. 1997 Feb;3(2):231-4 [9018245.001]
  • [Cites] Cancer Treat Rev. 1998 Apr;24(2):133-56 [9728423.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2076-81 [15781615.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):35-40 [15922855.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2381-402 [16226460.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8570-6 [16361539.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):484-91 [16734726.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5582-91 [16740693.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):253-67 [18354415.001]
  • [Cites] Cancer Sci. 2008 Apr;99(4):738-46 [18377425.001]
  • [Cites] Mol Carcinog. 2008 Sep;47(9):701-6 [18176935.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):474-8 [10581039.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):491-5 [10767357.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4816-22 [11156240.001]
  • (PMID = 18980972.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102701-06; United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / P50 CA102701-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Transcription Factors; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.- / histone methyltransferase; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ NIHMS113856; NLM/ PMC2690708
  •  go-up   go-down


100. Montgomery E, Mamelak AJ, Gibson M, Maitra A, Sheikh S, Amr SS, Yang S, Brock M, Forastiere A, Zhang S, Murphy KM, Berg KD: Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
  • The authors identified upregulation of Claudins 3, 4, and 7 in gastric adenocarcinoma using Affymetrix U-133 oligonucleotide microarrays and immunohistochemistry (IHC).
  • The authors hypothesized that Claudins would be similarly overexpressed in Barrett's esophagus (BE)/adenocarcinoma.
  • Claudins 3, 4, and 7 gene expression was analyzed by Affymetrix U-133 microarrays in three esophageal adenocarcinomas, one case of BE, and three normal esophagi.
  • IHC validation was performed using tissue microarrays constructed from esophageal resection specimens containing squamous (44 cases), gastric (40 cases), and non-dysplastic BE (16 cases), low-grade and high-grade dysplasia (16 and 26 cases), adenocarcinoma (58 cases), and nodal metastases (27 cases).
  • By IHC, Claudin 3 expression was 1+ in most (>95%) normal squamous or gastric tissues and 2+ to 4+ in more than 80% of high-grade dysplasia, adenocarcinoma, and metastases specimens.
  • Claudin 4 protein expression was 2+ or less in most squamous and gastric mucosa (>90%) but 3+ or 4+ in BE, low- and high-grade dysplasia, adenocarcinoma, and metastases specimens (>90%).
  • In high-grade dysplasia, adenocarcinoma, and metastases, Claudin 7 was less intense, with 60% to 70% staining 3+ or 4+ and 30% to 40% staining weakly (1+ or 2+).
  • The findings suggest that alterations in Claudin proteins are an early event in tumorigenesis and may provide targets for diagnosis and directed therapy for esophageal adenocarcinoma and its precursors.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540726.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down






Advertisement